US3755332A - Substituted 4 indazolaminoquinolines - Google Patents
Substituted 4 indazolaminoquinolines Download PDFInfo
- Publication number
- US3755332A US3755332A US00159061A US3755332DA US3755332A US 3755332 A US3755332 A US 3755332A US 00159061 A US00159061 A US 00159061A US 3755332D A US3755332D A US 3755332DA US 3755332 A US3755332 A US 3755332A
- Authority
- US
- United States
- Prior art keywords
- mixture
- added
- ethanol
- dissolved
- indazolamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 89
- SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical compound C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 claims description 26
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 28
- 150000003839 salts Chemical class 0.000 abstract description 19
- 239000002253 acid Substances 0.000 abstract description 11
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 7
- 150000001204 N-oxides Chemical class 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 239000002220 antihypertensive agent Substances 0.000 abstract description 3
- 239000003430 antimalarial agent Substances 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 228
- 239000000203 mixture Substances 0.000 description 121
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- 239000000243 solution Substances 0.000 description 88
- 239000000047 product Substances 0.000 description 77
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 57
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 52
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- 238000010992 reflux Methods 0.000 description 42
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 38
- 238000001953 recrystallisation Methods 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000002244 precipitate Substances 0.000 description 25
- 239000012458 free base Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 22
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 21
- KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 18
- 229940098779 methanesulfonic acid Drugs 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- -1 pbromophenyl Chemical group 0.000 description 17
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- 239000003610 charcoal Substances 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 239000000908 ammonium hydroxide Substances 0.000 description 10
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- HQAIROMRVBVWSK-UHFFFAOYSA-N 4-chloro-2-methylquinoline Chemical compound C1=CC=CC2=NC(C)=CC(Cl)=C21 HQAIROMRVBVWSK-UHFFFAOYSA-N 0.000 description 9
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 230000001376 precipitating effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 150000005637 4-haloquinolines Chemical class 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229910052736 halogen Chemical group 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 5
- UASKCSYIRXPZPX-UHFFFAOYSA-N ethyl 4-chloro-2-methylquinoline-3-carboxylate Chemical compound C1=CC=CC2=C(Cl)C(C(=O)OCC)=C(C)N=C21 UASKCSYIRXPZPX-UHFFFAOYSA-N 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- MHCWLERQNFATHZ-UHFFFAOYSA-N 2-methylindazol-6-amine Chemical compound C1=CC(N)=CC2=NN(C)C=C21 MHCWLERQNFATHZ-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000078 anti-malarial effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002178 crystalline material Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002140 halogenating effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- ISRJCWLLGCDNPO-UHFFFAOYSA-N methyl 4-chloro-2-methylquinoline-3-carboxylate Chemical compound C1=CC=CC2=C(Cl)C(C(=O)OC)=C(C)N=C21 ISRJCWLLGCDNPO-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- MDELYEBAXHZXLZ-UHFFFAOYSA-N 1h-indazol-4-amine Chemical compound NC1=CC=CC2=C1C=NN2 MDELYEBAXHZXLZ-UHFFFAOYSA-N 0.000 description 2
- XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 2
- OTFFCAGPSWJBDK-UHFFFAOYSA-N 1h-indazol-7-amine Chemical compound NC1=CC=CC2=C1NN=C2 OTFFCAGPSWJBDK-UHFFFAOYSA-N 0.000 description 2
- RJFYXEGJMSZKIR-UHFFFAOYSA-N 2-methyl-6-nitroindazole Chemical compound C1=CC([N+]([O-])=O)=CC2=NN(C)C=C21 RJFYXEGJMSZKIR-UHFFFAOYSA-N 0.000 description 2
- DRRARKIFTNKQDW-UHFFFAOYSA-N 3-chloro-2h-indazol-6-amine Chemical compound C1=C(N)C=CC2=C(Cl)NN=C21 DRRARKIFTNKQDW-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- QTYCALFKBCOYLW-UHFFFAOYSA-N 4,7-dichloro-2-methylquinoline Chemical compound C1=CC(Cl)=CC2=NC(C)=CC(Cl)=C21 QTYCALFKBCOYLW-UHFFFAOYSA-N 0.000 description 2
- KQXIMYKBHAMAAM-UHFFFAOYSA-N 4-chloro-2-methyl-7-(trifluoromethyl)quinoline Chemical compound C1=CC(C(F)(F)F)=CC2=NC(C)=CC(Cl)=C21 KQXIMYKBHAMAAM-UHFFFAOYSA-N 0.000 description 2
- LLRQVSZVVAKRJA-UHFFFAOYSA-N 4-chloro-7-(trifluoromethyl)quinoline Chemical compound ClC1=CC=NC2=CC(C(F)(F)F)=CC=C21 LLRQVSZVVAKRJA-UHFFFAOYSA-N 0.000 description 2
- RZWXKIREBJOMAK-UHFFFAOYSA-N 4-chloro-7-methyl-2-phenylquinoline Chemical compound N=1C2=CC(C)=CC=C2C(Cl)=CC=1C1=CC=CC=C1 RZWXKIREBJOMAK-UHFFFAOYSA-N 0.000 description 2
- YAYHLQSQQGGRRE-UHFFFAOYSA-N 6-methyl-5h-[1,3]dioxolo[4,5-g]quinolin-8-one Chemical compound C1=C2NC(C)=CC(=O)C2=CC2=C1OCO2 YAYHLQSQQGGRRE-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- DVKLXZSPPZIMIQ-UHFFFAOYSA-N ethyl 4,7-dichloro-2-methylquinoline-3-carboxylate Chemical compound C1=C(Cl)C=CC2=C(Cl)C(C(=O)OCC)=C(C)N=C21 DVKLXZSPPZIMIQ-UHFFFAOYSA-N 0.000 description 2
- KWYQZEQRIMVMTH-UHFFFAOYSA-N ethyl 4,7-dichloroquinoline-3-carboxylate Chemical compound C1=C(Cl)C=CC2=C(Cl)C(C(=O)OCC)=CN=C21 KWYQZEQRIMVMTH-UHFFFAOYSA-N 0.000 description 2
- SKBIFKCXMGRLLK-UHFFFAOYSA-N ethyl 4-chloro-7-(trifluoromethyl)quinoline-3-carboxylate Chemical compound C1=C(C(F)(F)F)C=CC2=C(Cl)C(C(=O)OCC)=CN=C21 SKBIFKCXMGRLLK-UHFFFAOYSA-N 0.000 description 2
- OZOMNKPYBWQMAH-UHFFFAOYSA-N ethyl 7-methyl-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(C)C=CC2=C(O)C(C(=O)OCC)=CN=C21 OZOMNKPYBWQMAH-UHFFFAOYSA-N 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- 229940093858 ethyl acetoacetate Drugs 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- VYFOAVADNIHPTR-UHFFFAOYSA-N isatoic anhydride Chemical compound NC1=CC=CC=C1CO VYFOAVADNIHPTR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
- CQVKMVQRSNNAGO-UHFFFAOYSA-N 2-[4-formyl-3-methyl-n-(2-methylsulfonyloxyethyl)anilino]ethyl methanesulfonate Chemical compound CC1=CC(N(CCOS(C)(=O)=O)CCOS(C)(=O)=O)=CC=C1C=O CQVKMVQRSNNAGO-UHFFFAOYSA-N 0.000 description 1
- VNWMXFJTEJZBPW-UHFFFAOYSA-N 2-benzyl-4-chloroquinoline Chemical compound N=1C2=CC=CC=C2C(Cl)=CC=1CC1=CC=CC=C1 VNWMXFJTEJZBPW-UHFFFAOYSA-N 0.000 description 1
- IWPBWVZEOVCZRX-UHFFFAOYSA-N 2-methyl-5-nitroindazole Chemical class C1=C([N+]([O-])=O)C=CC2=NN(C)C=C21 IWPBWVZEOVCZRX-UHFFFAOYSA-N 0.000 description 1
- IIABTAZQWRTZHG-UHFFFAOYSA-N 2-methyl-7-(trifluoromethyl)-1h-quinolin-4-one Chemical compound C1=C(C(F)(F)F)C=C2NC(C)=CC(=O)C2=C1 IIABTAZQWRTZHG-UHFFFAOYSA-N 0.000 description 1
- WXYKQNAKEPRCGF-UHFFFAOYSA-N 2-methylquinoline-3-carboxylic acid Chemical compound C1=CC=C2C=C(C(O)=O)C(C)=NC2=C1 WXYKQNAKEPRCGF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IBTQINLHMGQUJU-UHFFFAOYSA-N 3-chloro-6-nitro-2h-indazole Chemical compound C1=C([N+](=O)[O-])C=CC2=C(Cl)NN=C21 IBTQINLHMGQUJU-UHFFFAOYSA-N 0.000 description 1
- KUVLLVOLQPRLGV-UHFFFAOYSA-N 4,6-dichloro-2-phenylquinoline Chemical compound C1=C(Cl)C2=CC(Cl)=CC=C2N=C1C1=CC=CC=C1 KUVLLVOLQPRLGV-UHFFFAOYSA-N 0.000 description 1
- SGONXZRSLCMWGK-UHFFFAOYSA-M 4,7-dichloro-1-methylquinolin-1-ium;iodide Chemical compound [I-].C1=C(Cl)C=C2[N+](C)=CC=C(Cl)C2=C1 SGONXZRSLCMWGK-UHFFFAOYSA-M 0.000 description 1
- VHGJNAHFEWJQKX-UHFFFAOYSA-N 4,7-dichloro-1-oxidoquinolin-1-ium Chemical compound C1=C(Cl)C=C2[N+]([O-])=CC=C(Cl)C2=C1 VHGJNAHFEWJQKX-UHFFFAOYSA-N 0.000 description 1
- AYSCIYSRYOMFTP-UHFFFAOYSA-M 4-chloro-1,2-dimethylquinolin-1-ium;iodide Chemical compound [I-].C1=CC=CC2=[N+](C)C(C)=CC(Cl)=C21 AYSCIYSRYOMFTP-UHFFFAOYSA-M 0.000 description 1
- ONNDFDQMHCNEGF-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)quinoline Chemical compound C1=CC=CC2=NC(C(F)(F)F)=CC(Cl)=C21 ONNDFDQMHCNEGF-UHFFFAOYSA-N 0.000 description 1
- WABDZSKKLDCIRM-UHFFFAOYSA-N 4-chloro-6-methoxy-2-methylquinoline Chemical compound N1=C(C)C=C(Cl)C2=CC(OC)=CC=C21 WABDZSKKLDCIRM-UHFFFAOYSA-N 0.000 description 1
- JUDKYVTYOZVODY-UHFFFAOYSA-N 4-chloro-6-methoxy-2-phenylquinoline Chemical compound C1=C(Cl)C2=CC(OC)=CC=C2N=C1C1=CC=CC=C1 JUDKYVTYOZVODY-UHFFFAOYSA-N 0.000 description 1
- BBZQRRHOPBBNRO-UHFFFAOYSA-N 4-chloro-7-fluoro-2-methylquinoline Chemical compound C1=CC(F)=CC2=NC(C)=CC(Cl)=C21 BBZQRRHOPBBNRO-UHFFFAOYSA-N 0.000 description 1
- KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 1
- BPTYMRSBTUERSW-UHFFFAOYSA-N 6-chloro-1h-indazol-3-amine Chemical compound ClC1=CC=C2C(N)=NNC2=C1 BPTYMRSBTUERSW-UHFFFAOYSA-N 0.000 description 1
- ORZRMRUXSPNQQL-UHFFFAOYSA-N 6-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2C=NNC2=C1 ORZRMRUXSPNQQL-UHFFFAOYSA-N 0.000 description 1
- OWPLFJSQLPTCHS-UHFFFAOYSA-N 7-(trifluoromethyl)-1H-quinolin-4-one Chemical compound FC(F)(F)C1=CC=C2C(O)=CC=NC2=C1 OWPLFJSQLPTCHS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FMBGYAMLOKMHFK-UHFFFAOYSA-N 8-chloro-6-methyl-[1,3]dioxolo[4,5-g]quinoline Chemical compound C1=C2OCOC2=CC2=NC(C)=CC(Cl)=C21 FMBGYAMLOKMHFK-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 101710167853 N-methyltransferase Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
- SQAUUQRBOCJRCW-UHFFFAOYSA-N diethyl 2-acetylpropanedioate Chemical compound CCOC(=O)C(C(C)=O)C(=O)OCC SQAUUQRBOCJRCW-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- OXNSYUQJYGBUAZ-UHFFFAOYSA-N ethyl 4-chloro-7-methylquinoline-3-carboxylate Chemical compound C1=C(C)C=CC2=C(Cl)C(C(=O)OCC)=CN=C21 OXNSYUQJYGBUAZ-UHFFFAOYSA-N 0.000 description 1
- KAXJGTFTNGYKFK-UHFFFAOYSA-N ethyl 4-oxo-2-phenyl-1h-quinoline-3-carboxylate Chemical compound N1C2=CC=CC=C2C(=O)C(C(=O)OCC)=C1C1=CC=CC=C1 KAXJGTFTNGYKFK-UHFFFAOYSA-N 0.000 description 1
- YHUWNMJUAZJACG-UHFFFAOYSA-N ethyl 4-oxo-7-(trifluoromethyl)-1h-quinoline-3-carboxylate Chemical compound FC(F)(F)C1=CC=C2C(=O)C(C(=O)OCC)=CNC2=C1 YHUWNMJUAZJACG-UHFFFAOYSA-N 0.000 description 1
- DGWOEPLHTLXEEL-UHFFFAOYSA-N ethyl 7-chloro-2-methyl-4-oxo-1h-quinoline-3-carboxylate Chemical compound ClC1=CC=C2C(=O)C(C(=O)OCC)=C(C)NC2=C1 DGWOEPLHTLXEEL-UHFFFAOYSA-N 0.000 description 1
- XWMCHSWUDMFGSW-UHFFFAOYSA-N ethyl 7-chloro-4-oxo-1h-quinoline-3-carboxylate Chemical compound ClC1=CC=C2C(=O)C(C(=O)OCC)=CNC2=C1 XWMCHSWUDMFGSW-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSXRWZBTVAZNSF-UHFFFAOYSA-N hydron;quinoline;chloride Chemical compound Cl.N1=CC=CC2=CC=CC=C21 PSXRWZBTVAZNSF-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XSWODDQKGOXFFU-UHFFFAOYSA-N methyl 2-methyl-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=CC=C2C(=O)C(C(=O)OC)=C(C)NC2=C1 XSWODDQKGOXFFU-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-M quinoline-3-carboxylate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-M 0.000 description 1
- JWEQRJSCTFBRSI-PCLIKHOPSA-N rboxylate Chemical compound COC(=O)C1C(N2C3=O)C4=CC=CC=C4OC1(C)N=C2S\C3=C\C(C=1)=CC=C(OC)C=1COC1=CC=CC=C1C JWEQRJSCTFBRSI-PCLIKHOPSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
Definitions
- ABSTRACT Substituted indazolaminoquinolines, acid addition salts thereof as well as N-oxides thereof are antiinflammatory, anti-hypertensive and anti-malarial agents.
- Illustrative embodiments are 7-ch1oro-4-(6- indazo1amino)-quino1ine and ethyl 7-ch1oro-4-(6- indazolamino)-quino1ine-3-carboxy1ate.
- the present invention relates to a novel class of chemical compounds.
- the present invention pertains to compounds of the general formula wherein R is hydrogen or halogen
- R is hydrogen, lower alkyl, benzyl, phenyl, pbromophenyl, p-chlorophenyl, carboxy, carbo(- lower alkoxy), or trifluoromethyl;
- R and R are each hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, or trifluoromethyl, or R and R are methylenedioxy when combined and adjacent;
- R is hydrogen or lower alkyl
- R is hydrogen, lower alkyl, carboxy or carbo(lower alkoxy);
- amino bridge between the indazole moiety and the quinoline, moiety can be attached to the 3-, 4-, 5-, 6-, or 7- position of the indazole moiety.
- R can be on any of the four ranging free carbon atoms of these positions.
- halogen as used herein is intended to cover chlorine, bromine and iodine, preferred is chlorine; lower alkyl is intended to cover alkyl groups of from one to six carbon atoms such as methyl, ethyl, propyl, butyl, sec.-butyl, pentyl, isopentyl, hexyl, and the' like.
- the preferred, substituent is methyl; lower alkoxy is intended to cover alkoxy groups containing from one to four carbon atoms such as methoxy, ethoxy, propoxy or butoxy, preferably methoxy and ethoxy.
- salts of the basic amino compounds are intended to cover salts of the basic amino compounds, said salts being derived from non-toxic inorganic or organic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, lactic, succinic, malic, maleic, aconitic, phthalic, tartaric, pamoic, etc.
- N-oxides. thereof as used herein is intended to cover compounds of Formula I in which the l-oxide is at the l-position of the quinoline moiety.
- the compounds of the present invention may be further substituted by a lower aklyl (methyl) group at either the 2-position of the indazole moiety or at the 1- position of the quinoline moiety.
- a lower aklyl (methyl) group at either the 2-position of the indazole moiety or at the 1- position of the quinoline moiety.
- R,, R,, R R,, R, and R are as defined above and X is halogen, preferably chlorine, bromine, or iodine.
- a 4-hydroxyquinoline of Formula II is reacted with a halogenating agent to form the corresponding 4-haloquinoline (Ila).
- the 4-haloquinoline (Ila) is then condensed with the aminoindazole of choice (III) to yield the hydrohalide salt of the indazolaminoquinoline (IV) which, if desired, may be converted to the free base by treatment with a base in the usual manner.
- R, or R is a carboxy moiety
- this group may, if desired, be removed by decarboxylation procedures known to the art to form compounds of general Formula I supra wherein R, or R is hydrogen.
- R, l-Methyl-4-(6-indazolimino)-R in a compound of Formula I is carboxy
- the corresponding compound wherein R, and R is carbalkoxy is first prepared and saponified in the usual manner.
- a 4-hydroxyquinoline of general Formula II is reacted with a halogenating agent, such as, a phosphorous pentahalide and illustratively phosphorous pentachloride, by refluxing the reactants in a solution of a phosphorous oxyhalide, in particular, phosphorous oxychloride. After heating for from about I to about 3 hours, the reaction mixture is cooled, and the product isolated.
- a halogenating agent such as, a phosphorous pentahalide and illustratively phosphorous pentachloride
- the isolation procedure is carried out by quenching the reaction mixture with ice, neutralizing with aqueous ammonia and collecting the solid precipitate thus formed. This solid is thoroughly extracted with hot organic solvents such as ether, or petroleum ether, to yield the 4-haloquinoline of general Formula (lla).
- the condensation of the aminoindazole (III) with the 4-haloquinoline (Ila) may be accomplished by any of three general procedures.
- the two components may be fused together; or they may be heated together in a solvent which is inert to the present reaction, such as acetone, dimethylformamide, dimethylsulfoxide, chloroform, acetonitriie, etc., or the reaction may be carried out in dilute mineral acid such as, for example, dilute hydrochloric acid. While the ratio of reactants is not critical, it is preferred to utilize a 1:1 molar ratio of quinoline to indazole. V
- the components are heated to a temperature of about 130l60C for a period of from about 3 to about 10 minutes.
- the reaction mixture becomes solid, and is then cooled, dissolved in aqueous alkanol, suitably aqueous ethanol, made basic by the addition of, most suitably, aqueous ammonia and the product precipitated by the addition of water.
- aqueous alkanol suitably aqueous ethanol
- the product is then removed by filtration and recrystallized most suitably from ethanol or ethyl acetate.
- the reactants are dissolved in dry acetone and heated under reflux for a period of from about one-half to about 40 hours.
- the reaction mixture is then cooled and the product isolated as the hydrochloride salt.
- this hydrochloride salt may be con-- verted to the free base by solution in aqueous alcohol, basification, suitably with aqueous ammonia, and precipitation with water.
- the precipitate is then collected, dried and recrystallized from a suitable solvent such as ethanol or ethyl acetate.
- the components are suspended in dilute hydrochloric acid, suitably from about 0.1N to about 5N acid and heated under reflux from about 2 to about hours.
- the reaction mixture is cooled, and the hydrochloride salt of the product isolated by filtration. If desired, the hydrochloride salt is then converted into the base in the manner set forth above.
- the indazolaminoquinolines of the present invention are characterized by antiinflammatory, anti-hypertensive as well as anti-malarial properties.
- Pharmacological test data has been obtained illustrating the therapeutic activity characterizing the compounds of the present invention.
- the daily dosages are between about 10 mg/kg and 400 mg/kg of the mammal.
- the compounds of the present invention demonstrate the properties of inhibiting and reducing inflammation, of lowering blood pressure and of favorably influencing malaria. They are thus useful as antiinflammatory anti-hypertensive and anti-malarial agents.
- the anti-inflammatory property of this class of compounds can be conveniently observed in the laboratory model in such art-recognized tests as the turbidity model, U.V. erythema test, anti-carrageenin, and adjuvant arthritis screens.
- turbidity model test inhibition of heat coagulation of serum proteins was observed in rats at dosages of mg/kg on subcutaneous administration.
- anti-hypertensive properties of the compounds of this invention have been domonstrated in such artrecognized anti-hypertensive tests as the tyrosine hydroxylase inhibition screen, the mouse norepinephrine release screen and tests with unanaesthetized DOCA hypertensive rats.
- the compounds of the present invention also exhibit anti-malarial properties.
- the efiicacy of the compounds was determined in the imidazole N-methyl transferase test. Inhibition was observed at concentrations from between 10 molar to l0 molar.
- the indazolaminoquinolines have very favorable therapeutic index; they are active in low concentrations while their LD values are very high.
- the indazolaminoquinolines of the present invention are administered topically, parenterally or orally to achieve an anti-inflammatory, anti-hypertensive or anti-malarial effect, in any of the usual pharmaceutical forms.
- These include solid and liquid unit oral dosage forms such as tablets, capsules, powders, suspension, solutions, syrups and the like, including sustained release preparations, and fluid injectable forms such as sterile solutions and suspensions.
- the compounds When administered topically, the compounds are compounded into pharmaceutically acceptable lotions, creams, ointments, powders or sprays.
- dosage form as used in this specification and the claims refer to physically discrete units to be administered in single or multiple dosage form to animals, each unit containing a predetermined quantity of active material in association with the required diluent, carrier or vehicle.
- the quantity of active material is that calculated to produce the desired therapeutic effect upon administration of one or more of such units.
- Powders are prepared by comminuting the compound to a suitably fine size and mixing with a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch. sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
- a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch. sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
- Capsules ae made by preparing a powder mixture as described above and filling formed gelatin sheaths.
- a lubricant such as talc, magnesium stearate and calcium stearate can be added to the powder mixture as an adjuvant before the filling operation;
- a glidant such as colloidal silica may be added to improve flow properties;
- a disintegrating or solubilizing agent may be added to improve the availability of the composition when the capsule is ingested.
- Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
- a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base such as starch, sucrose, kaolin, dicalcium phosphate and the like.
- the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials
- powder mixture can be run through the tablet machine and the resulting imperfectly formed slugs broken into granules.
- the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
- the lubricated mixture is then compressed into tablets.
- the medicaments can also be combined with free flowing inert carriers and compressed into tablets directly without going through the granulating or slugging steps.
- a protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dystuffs can be added to these coatings to distinguish different unit dosages.
- Oral fluids such as syrups and elixirs can be prepared in unit dosage form so that a given quantity, e.g., a teaspoonful, contains a predetermined amount of the compound.
- Syrups can be prepared by dissolving the compound in a suitably flavored aqueous sucrose solution while elixirs are prepared through the use of a nontoxic alcoholic vehicle.
- Suspensions can be formulated by dispersing the composition in a nontoxic vehicle in which it is insoluble.
- fluid unit dosage forms can be prepared by suspending or dissolving a measured amount of the compound in a non-toxic liquid vehicle suitable for injection such as an aqueous or oleaginous medium.
- a measured amount of the compound is placed in a vial and the vial and its contents are sterilized and sealed.
- An accompanying vial or vehicle can be provided for mixing prior to administration.
- One important embodiment of the present invention is the pharmaceutically acceptable non-toxic acid addition salts of these indazolaminoquinolines as well as the N-oxides.
- EXAMPLE 2 4-(6-lndazolamino)-quinaldine 13.3 g. (0.1 mole) of 6-amino-indazole was suspended in 750 ml. of 2N HCl. To this mixture was added 17.7 g (0.1 mole) of 4-chloro-quinaldine and the mixture was refluxed for 5 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The 4-(6-indazolamino)quinaldine hydrochloride was dissolved in 500 ml. of water and the pH of this mixture was adjusted to 8-9 with 10% NPLOH. The compound that precipitated was collected on a Buchner funnel and washed well with water and dried over-night in vacuo.
- EXAMPLE 6 7-Trifluoromethyl-4-(6-indazolamino)quinoline a.
- a mixture of 25 g. of 4-hydroxy-7-trifluoromethylquinoline and 150 ml. of phosphorous oxychloride was refluxed with stirring for a period of four hours. The excess POCl was removed in vacuo to give a syrupy residue. This was cooled, 100 ml. of ethanol was added and the mixture was stirred for 30 minutes. The resulting solid was filtered off and suspended in a mixture of alcohol and water; the pH of this mixture was adjusted to 9-10 with Nl-LOH. A crystalline compound precipitated which was filtered off, washed well with water and dissolved in 300 ml. of ether. The ether solution was dried over Na SO,, filtered and concentrated in vacuo to give a crystalline compound identified as 4- chloro-7-trifluoromethylquinoline, m.p. 66-69 (22.3 g.).
- EXAMPLE 8 7-Chloro-4-(5-indazolamino)quinaldine A mixture of 7.3 g. of 4,7-dichloroquinaldine and 4.6 g. of S-aminoindazole were dissolved in 200 ml. of 2 N HCl and heated under reflux for 7 hours. The reaction mixture was allowed to cool overnight and the hydrochloride salt of the product was collected. The 7- chloro-4-(5-indazolamino)quinaldine hydrochloride was suspended in 50 m1. of ethanol and was basified with concentrated NH OH. The suspension was stirred for 30 minutes, the solid product was collected and was washed well with water. After recrystallization from ethyl acetate, the product melted at 300-302. Yield: 2.1 g. Analysis for C l-l ClN Calc'd.: C, 66.13; H, 4.24; N, 18.15
- EXAMPLE 11 4-(3-Chloro-6-indazolamino)quinaldine A solution of 7.5 g. (0.045 mole) of 6-amino-3- chloroindazole and 7.95 g. (0.045 mole) of 4- chloroquinaldine in 200 m1. of 2N HCl was heated under reflux for 7 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The 4-(3-chloro-6-indazolamino)-quinaldine hydrochloride was suspended in a mixture of 200 ml.
- EXAMPLE 12 4-( 5-lndazolamino)-7-trifluorornethylquinaldine a.
- a mixture of 3-trifluorornethylaniline (129.0 g. 0.8 mole) and ethyl acetoacetate (104.2 g., 0.8 moles) was stored in a vacuum dessicator over CaCl, until the water uptake totalled 16.5 g. This mixture was then poured into refluxing phenyl ether (700 ml.). The mixture was boiled under reflux for 40 minutes, cooled to 70 and filtered. The resulting solid was triturated with ether and collected. m.p. 324-330; Yield 16.3 g.
- EXAMPLE 13 Ethyl 4-(6-indazolamino)quinaldine-3-carboxylate 6-Aminoindazole (1.6 g.) and ethyl 4- chloroquinaldine-3-carboxylate (3.0 g.) were combined and gently warmed. The mobile reaction mixture solidified. This was dissolved in hot ethanol, basified with 10% NH OH, and the product precipitated with water. Recrystallization of the product from aqueous ethanol yielded pale yellow prisms 1.5 g.: 33%), m.p. 226-7. Analysis for C H N O Calcd.: C, 69.35; H, 5.24; N, 16.18
- EXAMPLE 14 Ethyl 4-(4-indazolamino)-quinaldine-3-carboxylate 4.66 g. (0.035 mole) of 4-Amino-indazole was dissolved in 200 ml. of dry acetone. To this mixture was added 8.7 g. (0.035 mole) of ethyl 4-chloroquinaldine- 3-carboxy1ate and the mixture was refluxed for 24 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The ethyl 4- (4-indazolamino)-quinaldine-3-carboxylate hydrochloride was dissolved in 100 ml. of alcohol and 100 ml.
- EXAMPLE 1 5 Ethyl 7-chloro-4-( 6-indazolamino )-quinoline-3 carboxylate a.
- a mixture of 32.6 g. (0.13 mole) of ethyl 7-chloro- 4-hydroxyquinoline-3-carboxylate, 60 ml. of phosphorous oxychloride and 27 g. (0.13 mole) of phosphorous pentachloride was boiled under reflux for 2 hours and cooled. This mixture was poured slowly wwth stirring onto 1.5 Kg. of ice and 1.5 liters of NH OH keeping the mixture alkaline to phenolphthalein at all times. Stirring was continued for 2 hours and the precipitate was collected by filtration and air dried overnight.
- EXAMPLE 16 Ethyl 4-(S-indazolamino)-quinaldine-3-carboxylate 4.65 g. (0.035 mole) of S-Aminoindazole was dissolved in 250 ml. of dry acetone. To this mixture was added 8.7 g. (0.035 mole) of ethyl 4-chloroquinaldine- 3-carboxylate and the mixture was refluxed for 8 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. Ethyl 4-(5- indazolamino )-quinaldine-3-carboxylate hydrochloride was dissolved in 500 ml.
- EXAMPLE l7 Ethyl 4-( 7-indazolamino)-quinaldine-3-carboxylate 9.3 g. (0.07 mole) of 7-amino-indazole was dissolved in 500 ml. of dry acetone. To this mixture was added 17.4 g. (0.07 mole) of ethyl 4-chloroquinaldine-3- carboxylate and the mixture was refluxed for 21 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The ethyl 4-(7- indazolamino)-quinaldine-3-carboxylate hydrochloride was dissolved in 500 ml.
- EXAMPLE 18 Ethyl 7-trifluoromethyl-4-(6-indazolamino)-quinoline- 3-carboxylate a.
- a mixture of ethyl 4-hydroxy-7- trifluoromethylquinoline-3-carboxylate, 60 ml. of phosphorous oxychloride and 15 g. of phosphorous pentachloride was heated under reflux for 8 hours and cooled. This mixture was poured slowly with stirring into 1.5 Kg. of ice and made basic pH 10-11 with 10N NaOH. Stirring was continued for additional 2 hours and a gummy precipitate was obtained which crystallized upon standing. The crystalline compound was filtered and washed well with water. The solid was leached with 300 ml. of ether.
- Methyl 4-(6-indazolamino)-quinaldine-3-carboxylate 26.6 g. of 6-aminoindazole were dissolved in 850 ml. of dry acetone and to this mixture was added 47 g. (0.2 mole) of methyl 4-chloroquinaldine-3-ca.rboxylate. The mixture was refluxed with stirring for 6 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The salt [methyl 4-(6- indazolamino)-quinaldine-3-carboxylate hydrochloride] was dissolved in 400 ml. of 50 percent alcohol and the pH of this mixture was adjusted to 8-9 with 10% NH OH.
- EXAMPLE 23 Ethyl 2-phenyl-4-(5-indazolamino)-quinoline-3- carboxylate a.
- a mixture of 138 g. (0.82 mole) of isatoic anhydride, 253.8 g. (1.31 mole) of ethyl benzoylacetate, 4.6 g. of sodium hydroxide and 530 ml. of p-dioxane were heated under reflux for 8 hours. The solution was cooled; the product, ethyl 2-pheyl-4-hydroxyquinoline- 3-carboxylate, was collected and washed with ether. Yield: 48.5 g., m.p. 252-255.
- EXAMPLE 24 Methyl 4-(3-chloro-6-indazolamino)-quinaldine-3- carboxylate a. To a solution of ferrous sulfate (326 g.) in water (400 ml.) was added to a hot solution of 3-chloro-6- nitroindazole (39.4 g., 0.2 mole) in ethanol (410 ml.); concentrated NH Ol-l was then added (246 ml.). This mixture was heated under reflux on the steam bath for 20 minutes, NH,OH (400 ml.) was again added and heating was continued for an additional 20 minutes.
- ferrous sulfate 326 g.
- 3-chloro-6- nitroindazole 39.4 g., 0.2 mole
- ethanol 410 ml.
- concentrated NH Ol-l was then added (246 ml.). This mixture was heated under reflux on the steam bath for 20 minutes, NH,OH (400 ml.
- EXAMPLE 25 Ethyl 4-(S-indazolamino)-quinoline-2-carboxylate S-Amino-indazole (9.2 g., 0.069 mole) was dissolved in dry acetone (125 ml.) with heating and stirring.
- EXAMPLE 27 4-(2-methyl-6-indazolamino)-quinaldine 4-Ch1oroquinaldine (4.71 g., 0.0265 moles) was added to a solution of 2-methyl-6-aminoindazole (3.9 g., 0.0265 moles) in hydrochloric acid (3N, 80 ml.) and the resulting solution was heated under reflux for 16 hours. A yellow crystalline solid was precipitated on cooling.
- EXAMPLE 28 Ethyl 4-hydroxy-7-methylquinoline-3-carboxylate m-Toluidine (53.6 g., 0.5 moles) and diethyl ethoxymethylenemalonate (108.1 g., 0.5 moles) were mixed together and placed in a dessicator under vacuum over anhydrous calcium chloride. (water uptake of 4.9 g.) for 7 days. The resulting crotonate was added to refluxing phenyl ether (500 ml.), the solutionwas heated under reflux for 10 minutes, filtered at 70 and the product was triturated twice in ether (1 liter). There was obtained a yield of 6.1 g., m.p. 275-280 dec.
- EXAMPLE 29 Ethyl 4-(5-indazolamino)-7-methylquinoline-3- carboxylate A solution of ethyl 4-hydroxy-7-methylquinoline-3- carboxylate (6.1 g., 0.0264 moles) was heatedunder reflux in phosphorous oxychloride (35 ml.) for 1 hour. The reaction mixture was then poured into cracked ice about 1 liter), the pH was adjusted to 9-11 with 3N sodium hydroxide precipitating a white crystalline compound which was filtered and washed with water. A solution of the product in ether was dried over sodium sulfate/magnesium sulfate, charcoaled and evaporated to dryness yielding a solid on cooling with a melting point of 40-42 (5.7 g.).
- EXAMPLE 32 4-( 1-Methyl-5-indazolamino)-quinaldine a. l and 2-Methyl-5-nitroindazoles were prepared and separated as described by I. Barclay et al., J. Chem. Soc., 1941,113.
- EXAMPLE 33 Ethyl 7-chloro-4-(6-indazolamino)-quinaldine-3- carboxylate a. A mixture of 63.8 g of 3-ch1oroaniline and 101.6
- EXAMPLE 34 Ethyl 4-(2'-methyl-6-indazolamino)quinaldine-3- carboxylate a.
- a mixture of 600 g (0.611 mole) of 6- nitroindazole, 34.25 g (0.611 mole) of potassium hydroxide, 173.8 g (1.222 mole) of methyl iodide and 800 ml of methanol were heated under reflux for 4 hours.
- the reaction mixture was poured into 2.5 1 of ice water and the resulting precipitate collected by filtration.
- the dried precipitate 2-methyl-6-nitroindazole was recrystallized from methanol and melted at l58160C. (Lit. Barclay, J. Chem. Soc. 113 (1941) reported m.p. 159-160C.).
- EXAMPLE 35 Ethyl 4-(fi-indazolamino)-quinaldine-3-carboxylate-1- oxide a.
- Ethyl 4-chloroquinaldine-3-carboxylate (23.4 g: 0.175 mole) was dissolved in CHCl (250 ml).
- m- Chloroperbenzoic acid 29.4 g: 0.175 mole was dissolved in CHCl (250 ml) and added to the quinaldine solution; the resulting mixture was allowed to stand at room temperature for 72 hours.
- the reaction mixture was extracted with 5% Na CO (4 X 150 ml), then washed with H (3 X 200 ml).
- the chloroform solution was dried over K CO and the solvent removed under reduced pressure to yield a residue which crystallized on cooling, and trituration with petroleum ether. Yield 21 g., m.p. 127-129C.
- the obtained compound was ethyl 4-(6-indazolamino)- quinaldine-3-carboxylate-l-oxide.
- 6-Aminoindazole (10.01 g.: 0.0753 mole) was dissolved in EtOH (310 ml) and H 0 (45 ml).
- Ethyl 4- chloroquinaldine-3-carboxylate-l-oxide (20 g.; 0.0753 mole) dissolved in EtOH (50 ml) was added to the indazole solution with drops of concentrated l-iCl.
- the resulting mixture was refluxed for 24 hours and concentrated in vacuo to a residual solid. This solid was suspended in H O, the suspension was basified with concentrated Nl-1 0l-1, and the resulting precipitate was collected and washed with 11 0.
- EXAMPLE 36 7-Chloro-4-(6-indazolamino)-quinoline-l-oxide a. 4,7-Dichloroquinoline (99 g, 0.5 mole) was dissolved in CHCl (300 ml) at room temperature. m- Chloroperbenzoic acid (80%, 101.4 g, 0.5 mole) suspended in Cl-lCl; (1 liter) was added to the quinoline solution. The resulting mixture was allowed to stand at room temperature for 48 hours. The Cl-lCl, solution was washed with 10% Na,CO solution (3 X 500 ml), then with H 0 (3 X 1 liter), dried over K,CO, and concentrated in vacuo.
- 6-Aminoindazole (13.7 g, 0.096 mole) was dissolved in EtOH (400 ml) and 11,0 (60 ml).
- 4,!- Dichloroquinoline-l-oxide (20.6 g, 0.096 mole) suspended in cold EtOH (200 ml) was added to the indazole solution.
- 6 drops of concentrated HCl the mixture was heated under reflux for 24 hours.
- the solvent was concentrated in vacuo and the residue was suspended in 11,0 (500 ml).
- the suspension was stirred with cooling and filtered.
- the precipitate was suspended in dilute EtOH (20%, 400 m1) and was basified with cone. NH OH, diluted well with 11,0 to give precipitate which was collected.
- EXAMPLE 38 4-(6-lndazolamino)-2-trifluoromethylquinoline Dimethane-sulfonate a. 4-1-1ydroxy-2-trifluoromethylquinoline was prepared by the method of A. S. Dey and M. M. Joulie', .1. 'Heterocyclic Chem., 2, 113 (1965), [2- trifluoromethy1-4-quinolinolsgeneral method a.].
- 6-Aminoindazole (9.4 g, 0.033 mole) was dissolved in acetonitrile ml) and concentrated hydrochloric acid (0.33 ml) was added.
- the precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (80 ml) to the mixture.
- 4-Hydroxy- Z-trifluoromethylquinoline (9.4 g; 033 mole) was added and the reaction mixture refluxed for 3% hrs., then cooled to room temperature. The solution was evaporated under vacuum and the residue dissolved in ethanol (400 ml). Concentrated aqueous ammonia was added to pH 9. The mixture was cooled and the free base (1.2 g) was filtered off and vacuum dried.
- Methanesul- 0.005 mole prepared by the method of RM. Peck, R.K. Preston, and HJ. Creech, J. Amer. Chem. Soc., 81, 3984 (1959)] was added and the solution was refluxed for 3 hr. After cooling, the hydrochloride salt of the product was filtered off and dissolved in 70 percent aqueous ethanol (50 ml). Concentrated aqueous ammonia was added to pH 8; the precipitated free base was filtered off and vacuum dried. This material was suspended in ethanol (25 ml) and methanesulfonic acid (1 equivalent) was added.
- EXAMPLE 41 4-(6-1ndazolamino)-6-methoxyquinoline Methanesul fonate 6-Aminoindazole (0.66 g; 0.005 mole) was dissolved in acetonitrile (25 ml) and concentrated hydrochloric acid (0.05 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide 12.5 ml) to the mixture, 4-ch1oro-6- methoxyquinoline (1 g; 0.005 mole) was added and the solution was refluxed for 3 hrs. The reaction mixture was cooled, and the product was filtered off then suspended in ethanol (100 ml) with warming.
- EXAMPLE 42 6-Chloro-4-(6-1ndazolamino)-2-phenylquinoline Methanesulfonate
- One Third Hydrate 6-Aminoindazole (533 mg; 4 m mole) was dissolved in acetonitrile (20 ml) and concentrated hydrochloric acid (0.04 ml) was added.
- the precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (10 ml) to the mixture.
- 4,6-Dichloro-2- phenylquinoline (1.1 g; 4 m mole) was added and the reaction mixture refluxed for 3% hr. then cooled to room temperature.
- the crystalline material was filtered off and dissolved in a mixture of water (7 ml) and ethanol (33 ml). Concentrated aqueous ammonia was added to pH 9. The mixture was cooled and the free base (1.15 g) was filtered off and vacuum dried. This material was suspended in ethanol (25 ml) and methanesulfonic acid (310 mg) was added. The resulting solution was evaporated to dryness and the residue recrystallized from ethanol/ethyl acetate to give the methanesulfonate, m.p. 290-295 dec.
- EXAMPLE 43 4-(6-Indazolarnino)quinoline Methanesulfonate 6-Aminoindazole (4.0 g, 0.03 mole) was dissolved in acetonitrile (150 ml) and concentrated hydrochloric acid (0.3 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylfonnamide ml) to the mixture. 4-Chloroquinoline (4.91 g, 0.03 mole) was added and the reaction mixture was refluxed for 2 hrs. and cooled to room temperature. The crystalline material was filtered off and then dissolved in a mixture of 2B ethanol (100 ml) and water (5 ml) with warming.
- 6-Aminoindazole (0.85 g) was dissolved in acetonitrile (35 ml) and concentrated hydrochloric acid (0.07 ml) was added.
- the precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (17.5 ml).
- 4-Chloro-7-methyl-2-phenylquinoline 1.7 g was added and the reaction mixture was refluxed for 3% hr.
- the reaction mixture was cooled to room temperature and the crystalline product filtered off, and dissolved in ethanol ml). Concentrated aqueous ammonia was added to pH 8 and the free base was precipitated by the addition of water (200 ml).
- EXAMPLE 46 4-(6-lndazolamino)-6-methoxy-2-phenylquinoline Methane-sulfonate 6-Aminoindazole (3.17 g; 23.8 mM) was dissolved in acetonitrile (125 ml) and concentrated hydrochloric acid (0.24 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (60 ml) to the mixture. 4-Chloro-6-methoxy-2- phenylquinoline (6.4 g; 23.8 mM) [prepared according to the method of B.P. Bangdiwala and C.M. Desai, Jour. Indian Chem. Soc., 31, 43 No.
- EXAMPLE 47 4-(6-lndazolamino)-6-hydroxy-2-phenylquinoline Methanesulfonate Monohydrate 4-( 16-Indazolamino )-6-methoxy-2-phenylquinoline hydrochloride (Ex. 46) (2.5 g) was dissolved in 48 percent hydrobromic acid (250 ml) and refluxed for 4 hrs. The crystalline material was filtered off, suspended in ethanol (150 ml) and brought into solution with concentrated ammonium hydroxide (25 ml). The free base was precipitated with water (800 ml), filtered off and dried.
- EXAMPLE 48 4-(6-lndazolamino)-6-methoxy-2-phenyl-7-trifluoromethylquinoline Methanesulfonate a. 4-Hydroxy-6-methoxy-7-trifluoromethyl-2- phenylquinoline (11.2 g) [prepared by the general procedure of 8.1. Bangdiwala, C.M. Desai, Jour. Indian Chem. Soc. 31, 43 (1954)] was dissolved in phosphorous oxychloride 100 ml) and refluxed for 40 minutes. it was then poured on ice and neutralized with strong ammonia. The precipitate (11.5 g) was filtered off and crystallized from ethanol (900 ml) to give 10.3 g of the pure product, m.p. 172.
- the free base was precipitated by the addition of 800 ml water. 3.3 g of the free base were suspended in hot ethanol (100 ml), methanesulfonic acid (730 mg; 1 eq) was added to give 3.4 g of the methanesulfonate salt which on recrystallization from ethanol/water (2 times) gave 2.4 g of the pure product, m.p. 340342.
- EXAMPLE 49 4-(6-lndazolamino)quinaldine Methanesulfonate 6-Aminoindazole (13.3 g; 0.1 M) was dissolved in acetonitrile (500 ml) and concentrated hydrochloric acid (1.0 ml) was added. The partially precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (250 ml) to the mixture. 4- Chloroquinaldine (17.7 g; 0.1 M) was added and the reaction mixture refluxed for 2% hours and cooled to room temperature.
- the precipitated material (28.5 g) was dissolved in a hot mixture of ethanol (500 ml) and water ml), concentrated ammonium hydroxide (60 ml) was added to the cooled solution and then diluted with water (2 liters).
- the precipitated free base (25.0 g) was dissolved in ethanol (650 ml) with warmthing and methanesulfonic acid (8.75 g; 1 eq.) was added to yield 29.5 g of the methanesulfonate salt which on recrystallization (3 times) from ethanol gave 15.8 g of the product, m.p. 238,240.
- EXAMPLE 50 4-(6-lndazolamino)-6-methoxyquinaldine Methanesulfonate 6-Aminoindazole (6.7 g) was dissolved in acetonitrile (400 ml) and concentrated hydrochloric acid (0.5 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (200 ml) to the mixture. 4-Chloro-6-methoxyquinaldine 10.5 g) [Schock, J. Amer. Chem. Soc. 79, 1,672, 1,675 (1957)] was added and the reaction mixture refluxed for 4 hours.
- the precipitated material (16.5 g) was suspended in ethanol (150 ml), concentrated ammonium hydroxide (30 ml) was added and the free base was precipitated from the clear solution by the addition of water (800 ml).
- the base 14 g was suspended in ethanol (150 ml) and methanesulfonic acid (7 g) was added.
- the precipitated methanesulfonate salt was recrystallized from ethanol (3 times) followed by crystallization from water to give 9 g of the product m.p. 202204. (The m.p. was 300 302 after recrystallization from ethanol).
- the reaction mixture was cooled to room temperature and the product was filtered off and suspended in ethanol (25 m1). Aqueous ammonia was added to pH 9 followed by water (8 ml). The mixture was refrigerated and the free base filtered off. This material was vacuum dried (500 mg) and suspended in ethanol and methanesulfonic acid (137 mg; 1 equiv.) was added. The solution was evaporated to dryness and the residue recrystallized from ethanol to give 650 mg of the methanesulfonate, m.p. 253255 de'c.
- EXAMPLE 52 4-(6-lndazolamino)-7-trifluoroquinaldine Methanesulfonate 7.5 g of 6-aminoindazole, 100 ml of acetonitrile, 0.7 m1 of concentrated hydrochloric acid, 50 ml of dimethylformamide and 13.8 g of 4-chloro-7-trifluoromethylquinaldine [prepared according to the procedure of G. Franchi, P. Vigne, Farmaco, Ed. Sci. 22 (11), 923-929 (1967)] were refluxed for 4 hours. The hydrochloride of the product formed a precipitate which was kept in the freezer overnight and the precipitate was filtered off.
- EXAMPLE 53 4-(6-lndazolamino)-6,7-methylenedioxyquinaldine Methanesulfonate a. 33.5 g of 3,4-methylenedioxyaniline, 32 g of ethylacetoacetate, 100 ml of benzene and 4 drops of concentrated hydrochloric acid were refluxed for hours. 4.5 ml of water was separated and the benzene solution evaporated. A dark red oil, 62.3 g, was obtained which crystallized, m.p. 80-82.
- R is hydrogen or halogen
- R is hydrogen, primary and secondary lower alkyl of one to six carbon atoms, benzyl, phenyl, pbromophenyl, p-chlorophenyl, or trifluoromethyl; each of R, and R is hydrogen, hydroxy, halogen, primary and secondary lower alkyl of one to six carbon atoms, lower alkoxy of one to four carbon atoms, or when R, is hydrogen, R is also trifluoromethyl; or R, and R, are methylenedioxy when combined and adjacent;
- R is hydrogen or lower alkyl of one to six carbon atoms
- R is hydrogen or primary and secondary lower alkyl of one to six carbon atoms, and wherein the amino bridge is attached to indazole at the 3-, 4-, 5-, 6- or 7- position; the pharmaceutically acceptable acid addition salts, or the N-oxides thereof, wherein the oxide is at the 1-position of the quinoline moiety.
- a compound as defined in claim 1 which is 4-(5- indazolamino)-quinaldine.
- a compound as defined in claim 1 which is 4-( 6- chloro-3-indazolamino)-quinaldine.
- a compound as defined in claim 1 which is 4-(6- indazolamino)-quinaldine.
- a compound as defined in claim 1 which is 4-(6- indazolamino)-6-methoxyquinoline.
- a compound as defined in claim 1 which is 4-(6- indazolamino)-6-hydroxy-2phenylquinoline.
- a compound as defined in claim I which is 4-(6- indazolamino)-6-methoxy-2phenyl-7-trifluoromethylquinoline.
- a compound as defined in claim 1 which is 4-(6- indazolamino )quinaldine.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Substituted indazolaminoquinolines, acid addition salts thereof as well as N-oxides thereof are anti-inflammatory, antihypertensive and anti-malarial agents. Illustrative embodiments are 7-chloro-4-(6-indazolamino)-quinoline and ethyl 7-chloro-4(6-indazolamino)-quinoline-3-carboxylate.
Description
ite if;
States atent 1 Wasley et a1.
[451 Aug. 28, 1973 SUBSTITUTED 4 INDAZOLAMINOQUINOLINES Inventors: Jan W. F. Wasley, Ossining;
Abraham Wajngurt, Riverdale, both of N.Y.
Assignee: Ciba-Geigy Corporation, Ardsley,
Filed: July 1, 1971 Appl. No.: 159,061
Related [1.8. Application Data Continuation-impart of Ser. No. 818,044, April 21, 1969, abandoned, and a continuation-in-part of Ser. No 725,176, April 29, 1968, abandoned.
US. Cl. 260/288 R, 260/286 R, 260/287 R,
260/289 R, 260/309, 424/258 Int. Cl C07d 33/50 Field of Search 260/287 R, 288 R Primary ExaminerDona1d G. Daus Attorney-Karl 1F. Jorda et a1.
[57] ABSTRACT Substituted indazolaminoquinolines, acid addition salts thereof as well as N-oxides thereof are antiinflammatory, anti-hypertensive and anti-malarial agents. Illustrative embodiments are 7-ch1oro-4-(6- indazo1amino)-quino1ine and ethyl 7-ch1oro-4-(6- indazolamino)-quino1ine-3-carboxy1ate.
16 Claims, No Drawings SUBSTITUTED 4 INDAZOLAMINOQUINOLINES CROSS-REFERENCE This is a continuation-in-part of copending application, Ser. No. 818,044, filed Apr. 21, 1969, and of application, Ser. No. 725,176, filed Apr. 29, 1968, both now abandoned.
DETAILED DESCRIPTION The present invention relates to a novel class of chemical compounds.
More specifically, the present invention pertains to compounds of the general formula wherein R is hydrogen or halogen;
R, is hydrogen, lower alkyl, benzyl, phenyl, pbromophenyl, p-chlorophenyl, carboxy, carbo(- lower alkoxy), or trifluoromethyl;
R and R are each hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, or trifluoromethyl, or R and R are methylenedioxy when combined and adjacent;
R is hydrogen or lower alkyl;
R, is hydrogen, lower alkyl, carboxy or carbo(lower alkoxy);
and pharmaceutically acceptable acid addition salts and N-oxides thereof.
It should be noted that the amino bridge between the indazole moiety and the quinoline, moiety can be attached to the 3-, 4-, 5-, 6-, or 7- position of the indazole moiety. R can be on any of the four ranging free carbon atoms of these positions.
The expression halogen" as used herein is intended to cover chlorine, bromine and iodine, preferred is chlorine; lower alkyl is intended to cover alkyl groups of from one to six carbon atoms such as methyl, ethyl, propyl, butyl, sec.-butyl, pentyl, isopentyl, hexyl, and the' like. The preferred, substituent is methyl; lower alkoxy is intended to cover alkoxy groups containing from one to four carbon atoms such as methoxy, ethoxy, propoxy or butoxy, preferably methoxy and ethoxy.
The expression pharmaceutically acceptable acid addition salts", as used herein, is intended to cover salts of the basic amino compounds, said salts being derived from non-toxic inorganic or organic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, lactic, succinic, malic, maleic, aconitic, phthalic, tartaric, pamoic, etc.
The expression N-oxides. thereof as used herein is intended to cover compounds of Formula I in which the l-oxide is at the l-position of the quinoline moiety.
The compounds of the present invention may be further substituted by a lower aklyl (methyl) group at either the 2-position of the indazole moiety or at the 1- position of the quinoline moiety. In such a case, the
halogenating R5 agent R, It
Ila
R,, R,, R R,, R, and R, are as defined above and X is halogen, preferably chlorine, bromine, or iodine.
As indicated above, a 4-hydroxyquinoline of Formula II is reacted with a halogenating agent to form the corresponding 4-haloquinoline (Ila). The 4-haloquinoline (Ila) is then condensed with the aminoindazole of choice (III) to yield the hydrohalide salt of the indazolaminoquinoline (IV) which, if desired, may be converted to the free base by treatment with a base in the usual manner.
Where R, or R, is a carboxy moiety, this group may, if desired, be removed by decarboxylation procedures known to the art to form compounds of general Formula I supra wherein R, or R is hydrogen.
Where R, l-Methyl-4-(6-indazolimino)-R in a compound of Formula I is carboxy, the corresponding compound wherein R, and R is carbalkoxy is first prepared and saponified in the usual manner.
In a specific embodiment of the present invention illustrating the preparation of the active compounds, a 4-hydroxyquinoline of general Formula II is reacted with a halogenating agent, such as, a phosphorous pentahalide and illustratively phosphorous pentachloride, by refluxing the reactants in a solution of a phosphorous oxyhalide, in particular, phosphorous oxychloride. After heating for from about I to about 3 hours, the reaction mixture is cooled, and the product isolated.
Generally, the isolation procedure is carried out by quenching the reaction mixture with ice, neutralizing with aqueous ammonia and collecting the solid precipitate thus formed. This solid is thoroughly extracted with hot organic solvents such as ether, or petroleum ether, to yield the 4-haloquinoline of general Formula (lla).
The condensation of the aminoindazole (III) with the 4-haloquinoline (Ila) may be accomplished by any of three general procedures. The two components may be fused together; or they may be heated together in a solvent which is inert to the present reaction, such as acetone, dimethylformamide, dimethylsulfoxide, chloroform, acetonitriie, etc., or the reaction may be carried out in dilute mineral acid such as, for example, dilute hydrochloric acid. While the ratio of reactants is not critical, it is preferred to utilize a 1:1 molar ratio of quinoline to indazole. V
In the fusion process, the components are heated to a temperature of about 130l60C for a period of from about 3 to about 10 minutes. The reaction mixture becomes solid, and is then cooled, dissolved in aqueous alkanol, suitably aqueous ethanol, made basic by the addition of, most suitably, aqueous ammonia and the product precipitated by the addition of water. The product is then removed by filtration and recrystallized most suitably from ethanol or ethyl acetate.
In the procedure involving the use of an inert solvent such as acetone, the reactants are dissolved in dry acetone and heated under reflux for a period of from about one-half to about 40 hours. The reaction mixture is then cooled and the product isolated as the hydrochloride salt. if desired, this hydrochloride salt may be con-- verted to the free base by solution in aqueous alcohol, basification, suitably with aqueous ammonia, and precipitation with water. The precipitate is then collected, dried and recrystallized from a suitable solvent such as ethanol or ethyl acetate.
In the procedure involving the use of a mineral acid such as dilute hydrochloric acid, the components are suspended in dilute hydrochloric acid, suitably from about 0.1N to about 5N acid and heated under reflux from about 2 to about hours. The reaction mixture is cooled, and the hydrochloride salt of the product isolated by filtration. If desired, the hydrochloride salt is then converted into the base in the manner set forth above.
As stated above, the indazolaminoquinolines of the present invention are characterized by antiinflammatory, anti-hypertensive as well as anti-malarial properties. Pharmacological test data has been obtained illustrating the therapeutic activity characterizing the compounds of the present invention. The daily dosages are between about 10 mg/kg and 400 mg/kg of the mammal.
The compounds of the present invention demonstrate the properties of inhibiting and reducing inflammation, of lowering blood pressure and of favorably influencing malaria. They are thus useful as antiinflammatory anti-hypertensive and anti-malarial agents. The anti-inflammatory property of this class of compounds can be conveniently observed in the laboratory model in such art-recognized tests as the turbidity model, U.V. erythema test, anti-carrageenin, and adjuvant arthritis screens. For instance, in the turbidity model test, inhibition of heat coagulation of serum proteins was observed in rats at dosages of mg/kg on subcutaneous administration.
In the anti-carrageenin screen, a diminution of swelling induced by carrageenin was observed in rats at dosages of 50-100 rug/kg p.o.
in the adjuvant arthritis screen protection was observed at dosages of 100 mg/kg when administered orally per day.
The anti-hypertensive properties of the compounds of this invention have been domonstrated in such artrecognized anti-hypertensive tests as the tyrosine hydroxylase inhibition screen, the mouse norepinephrine release screen and tests with unanaesthetized DOCA hypertensive rats.
The compounds of the present invention also exhibit anti-malarial properties. The efiicacy of the compounds was determined in the imidazole N-methyl transferase test. Inhibition was observed at concentrations from between 10 molar to l0 molar.
The indazolaminoquinolines have very favorable therapeutic index; they are active in low concentrations while their LD values are very high.
The indazolaminoquinolines of the present invention are administered topically, parenterally or orally to achieve an anti-inflammatory, anti-hypertensive or anti-malarial effect, in any of the usual pharmaceutical forms. These include solid and liquid unit oral dosage forms such as tablets, capsules, powders, suspension, solutions, syrups and the like, including sustained release preparations, and fluid injectable forms such as sterile solutions and suspensions. When administered topically, the compounds are compounded into pharmaceutically acceptable lotions, creams, ointments, powders or sprays. The term dosage form as used in this specification and the claims refer to physically discrete units to be administered in single or multiple dosage form to animals, each unit containing a predetermined quantity of active material in association with the required diluent, carrier or vehicle. The quantity of active material is that calculated to produce the desired therapeutic effect upon administration of one or more of such units.
Powders are prepared by comminuting the compound to a suitably fine size and mixing with a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch. sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
Capsules ae made by preparing a powder mixture as described above and filling formed gelatin sheaths. A lubricant such as talc, magnesium stearate and calcium stearate can be added to the powder mixture as an adjuvant before the filling operation; a glidant such as colloidal silica may be added to improve flow properties; a disintegrating or solubilizing agent may be added to improve the availability of the composition when the capsule is ingested.
Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base such as starch, sucrose, kaolin, dicalcium phosphate and the like. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the
powder mixture can be run through the tablet machine and the resulting imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The medicaments can also be combined with free flowing inert carriers and compressed into tablets directly without going through the granulating or slugging steps. A protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dystuffs can be added to these coatings to distinguish different unit dosages.
Oral fluids such as syrups and elixirs can be prepared in unit dosage form so that a given quantity, e.g., a teaspoonful, contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous sucrose solution while elixirs are prepared through the use of a nontoxic alcoholic vehicle. Suspensions can be formulated by dispersing the composition in a nontoxic vehicle in which it is insoluble.
For parenteral administration, fluid unit dosage forms can be prepared by suspending or dissolving a measured amount of the compound in a non-toxic liquid vehicle suitable for injection such as an aqueous or oleaginous medium. Alternatively a measured amount of the compound is placed in a vial and the vial and its contents are sterilized and sealed. An accompanying vial or vehicle can be provided for mixing prior to administration. I
One important embodiment of the present invention, particularly for preparing solid pharmaceutical formulations, is the pharmaceutically acceptable non-toxic acid addition salts of these indazolaminoquinolines as well as the N-oxides.
The following examples are given by way of illustrating the procedure used in preparing the compounds of the present invention without limiting the scope thereof in any way. The temperatures are given in degrees Centigrade.
EXAMPLE 1 7-Chloro-4-(6-indazolamino)-quinoline 13.3 g. (0.1 mole) of 6-amino-indazole was suspended in 500 ml. of 3N HCl and to this mixture was added 19.8 g. (0.1 mole) of 4,7-dichloroquinoline and this mixture was refluxed for 8 hours. (Aftr refluxing for one hour, a precipitate appeared which went back in solution after 2 hours. After refluxing for 3 hours, a new precipitate appeared.) The reaction mixture was stirred overnight, then cooled and the hydrochloride salt of the product was collected. The 7-chloro-4-(6- indazolamino)quinoline HCl was dissolved in 400 ml. of alcohol and 200 ml. of water and the solution was treated with charcoal. The clear solution was made basic to a pH 9-10 with 10% NH,OH. The compound that precipitated was collected on a Buchner funnel and washed well with water. After two recrystallizations from ethanol, the product melted at 253-254: Yield 8.0 g. after drying to constant weight for 3 days in vacuum oven at 100 Analysis for C H CIN,
Calc'd.: C, 65.20; H, 3.76; N, 19.07
Found C, 64.94; H, 3.67; N, 18.87
EXAMPLE 2 4-(6-lndazolamino)-quinaldine 13.3 g. (0.1 mole) of 6-amino-indazole was suspended in 750 ml. of 2N HCl. To this mixture was added 17.7 g (0.1 mole) of 4-chloro-quinaldine and the mixture was refluxed for 5 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The 4-(6-indazolamino)quinaldine hydrochloride was dissolved in 500 ml. of water and the pH of this mixture was adjusted to 8-9 with 10% NPLOH. The compound that precipitated was collected on a Buchner funnel and washed well with water and dried over-night in vacuo. After recrystallization from a mixture of ethyl acetate and isopropanol 2:1 using charcoal, the product melted at 240241; Yield 3.8 g. (after drying to constant weight for 3 days in vacuum oven at C). Analysis for C H N Calcd.: C, 74.73; H, 5.14; N, 20.43
Found C, 74.55; H, 4.90; N, 20.36
EXAMPLE 3 4-( 3-lndazolamino )-quinaldine A mixture of 3 g. (0.023 mole) of 3-aminoindazole and 4.07 g. (0.023 mole) of 4-chloro-quinaldine (obtained by the procedure described by A. Bamberger Berichte 55, 3371, (1922) was gently warmed at for period of 5 minutes. The mobile reaction mixture solidified and was then dissolved in a mixture of 200 ml. 50 percent ethanol and basified with 10% NH,OH (pH 9-10). The product was precipitated by the addition of 200 ml. of water. The product was filtered and washed well with water. The compound was recrystallized from ethanol; it melted at 264-265; Yield 4.3 g. Analysis for C H,-,N
Calcd.: C, 74.73; H, 5.14; N, 20.43
Found C, 74.94; H, 4.96; N, 20.58
EXAMPLE 4 4-(6-Chloro-3-indazolamino)-quinaldine A mixture of 8.3 g. (0.05 mole) of 6-chloro-3-aminoindazole and 8.5 g (0.05 mole) of 4-chloroquinaldine was gently warmed at 140 for a period of 5 minutes. The mobile reaction mixture solidified and was then dissolved in a mixture of 200 ml. 50 percent ethanol and basified with 10% NH OH (pH 9-10). The product was precipitated by the addition of 400 ml. of water. The product was filtered and washed well with water. The compound was recrystallized from ethanol. It melted at 23l-233; Yield 6.2 g. Analysis for C H CIN,
Calcd.: C, 66.13; H, 4.24; N, 18.15
Found C, 65.90; H, 4.17; N, 18.35
EXAMPLE 5 4-(5-lndazo1amino)-quina1dine 6.65 g. (0.05 mole) of 5-Aminoindazole was suspended in 220 ml. of 2N HC]. To this mixture was added 8.85 g (0.05 mole) of 4-chloroquinaldine and the mixture was refluxed for 5 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The 4-(5-indazolamino)quinaldine hydrochloride thus obtained was dissolved in 300 m1. of water and the pH of this mixture was adjusted to 8-9 with 10% NH OH. The compound that precipitated was collected on a Buchner funnel and washed well with water and dried overnight in vacuo. After recrystallization from ethyl acetate, the product melted at 298299; Yield 3.1 g. Analysis for C H N,
Calcd.: C, 74.43; H, 5.14; N, 20.43
Found C, 74.18; H, 5.23; N, 20.22
EXAMPLE 6 7-Trifluoromethyl-4-(6-indazolamino)quinoline a. A mixture of 25 g. of 4-hydroxy-7-trifluoromethylquinoline and 150 ml. of phosphorous oxychloride was refluxed with stirring for a period of four hours. The excess POCl was removed in vacuo to give a syrupy residue. This was cooled, 100 ml. of ethanol was added and the mixture was stirred for 30 minutes. The resulting solid was filtered off and suspended in a mixture of alcohol and water; the pH of this mixture was adjusted to 9-10 with Nl-LOH. A crystalline compound precipitated which was filtered off, washed well with water and dissolved in 300 ml. of ether. The ether solution was dried over Na SO,, filtered and concentrated in vacuo to give a crystalline compound identified as 4- chloro-7-trifluoromethylquinoline, m.p. 66-69 (22.3 g.).
b. 7.0 g. (0.053 mole) of 6-Aminoindazole was dissolved in 200 ml. of dry acetone. To this mixture was added 12.0 g. (0.053 mole) of 4-chloro-7-trifluoromethylquinoline obtained above and the mixture was heated under reflux for 36 hours. The reaction mixture was concentrated in vacuo and the hydrochloride salt of the product was collected. The 7-trifluoromethyl-4- (6-indazo1amino)-quinoline hydrochloride was suspended in 200 ml. of a mixture of 50 percent of alcohol and water and made basic with Nl-hOl-l (pH 8-9). The crystalline compound that precipitated was filtered and washed well with water. After crystallization from ethanol, the product melted at 266-268; Yield 4.0 g. Analysis for C H F N,
Calcd.: C, 62.19; H, 3.38; N, 17.06; F, 17.36
Found C, 62.27; H, 3.47; N, 17.00; F, 17.36
EXAMPLE 7 Analysis for C H N,
Calcd.: C, 78.54; H, 4.80; N, 16.6 Found C, 78.30; H, 4.92; N, 16.77
EXAMPLE 8 7-Chloro-4-(5-indazolamino)quinaldine A mixture of 7.3 g. of 4,7-dichloroquinaldine and 4.6 g. of S-aminoindazole were dissolved in 200 ml. of 2 N HCl and heated under reflux for 7 hours. The reaction mixture was allowed to cool overnight and the hydrochloride salt of the product was collected. The 7- chloro-4-(5-indazolamino)quinaldine hydrochloride was suspended in 50 m1. of ethanol and was basified with concentrated NH OH. The suspension was stirred for 30 minutes, the solid product was collected and was washed well with water. After recrystallization from ethyl acetate, the product melted at 300-302. Yield: 2.1 g. Analysis for C l-l ClN Calc'd.: C, 66.13; H, 4.24; N, 18.15
Found C, 65.97; H, 4.47; N, 17.86
EXAMPLE 9 4-(7-lndazolamino)-quinaldine A mixture of 6.1 g. of 7-aminoindazole and 8.1 g. of 4-chloroquinaldine were dissolved in 100 ml. 3N HCl and the solution was heated under reflux for 8 hours. The reaction mixture was allowed to stand overnight and then heated under reflux for an additional 8 hours. The hydrochloride salt of the product was collected and suspended in a mixture of 160 mls. of water and 40 mls. of ethanol and basified with 10% NH,OH. An additional 200 ml. of water were added to ensure complete precipitation of the product, which was collected by filtration. After recrystallization from ethanol, the product melted at 255-257; Yield 3.3 g. Analysis for CH N Calcd.: C, 74.43; H, 5.14; N, 20.43
Found C, 74.71; H, 5.33; N, 20.29
EXAMPLE l0 4-(4-lndazolamino)-quinaldine A mixture of 10 g. of 4-aminoindazole and 13.4 g. of 4-ch1oroquinaldine were dissolved in 100 ml. of 3N RC1 and the solution was heated under reflux for 16 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected, suspended in a mixture of 160 ml. of water and 40 m1. of ethanol and basified with 3N NaOH. The compound that precipitated was collected by filtration and washed well with water. After recrystallization from ethanol using charcoal, the product melted at 274-276. Yield 3.0 g. Analysis for C H N Calcd.: C, 74.43; H, 5.14; N, 20.43
Found C, 74.12; H, 5.08; N, 20.17
EXAMPLE 11 4-(3-Chloro-6-indazolamino)quinaldine A solution of 7.5 g. (0.045 mole) of 6-amino-3- chloroindazole and 7.95 g. (0.045 mole) of 4- chloroquinaldine in 200 m1. of 2N HCl was heated under reflux for 7 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The 4-(3-chloro-6-indazolamino)-quinaldine hydrochloride was suspended in a mixture of 200 ml.
- of ethanol and 200 m1. of water and basified with 3N NaOH. The compound that precipitated was collected by filtration and washed well with water. After two recrystallizations from ethyl acetate, the product was ob tained melting at 269270. Yield: 4.5 g. Analysis for C l-l CIN.
Calcd.: C, 66.13; H, 4.28; N, 18.15
Found C, 66.22; H, 4.51; N, 18.09
EXAMPLE 12 4-( 5-lndazolamino)-7-trifluorornethylquinaldine a. A mixture of 3-trifluorornethylaniline (129.0 g. 0.8 mole) and ethyl acetoacetate (104.2 g., 0.8 moles) was stored in a vacuum dessicator over CaCl, until the water uptake totalled 16.5 g. This mixture was then poured into refluxing phenyl ether (700 ml.). The mixture was boiled under reflux for 40 minutes, cooled to 70 and filtered. The resulting solid was triturated with ether and collected. m.p. 324-330; Yield 16.3 g.
b. A solution of 4-hydroxy-7-trifluoromethyl quinaldine obtained above (16.3 g., 0.072 mole) in POCl was boiled under reflux (oil bath 120) for 1 hour. This solution was cooled, poured onto a mixture of cracked ice and 50% NaOH (200 ml.), the pH was adjusted to -11 and the mixture was extracted with ether; the ether solution was dried over Na SO charcoaled and evaporated to dryness yielding an oil which crystallized on triturating with petroleum ether. Yield: 15.1 g., m.p. 4246.
c. S-Aminoindazole (8.1 g., 0.061 moles) was dissolved in dry acetone and to this solution 4-chloro-7- trifluoromethylquinaldine obtained above (15.1 g., 0.061 mole) was added; the resulting solution was boiled under reflux (oil bath 100) for 1 1 hours precipitating 4-(5-indazolamino)-7trifluoromethylquinaldine hydrochloride. The hydrochloride salt was suspended in EtOH/water (400 ml., 1:3), the suspension was basified with 3N NaOH and filtered; the product was washed well with water. The product melted at 278 after two recrystallizations from ethyl acetate. Yield: 1.4 g.
Analysis for C, H, -,F N
Calcd.: C, 63.15; H, 3.83; N, 16.37 Found C, 63.06; H, 3.94; N, 16.55
EXAMPLE 13 Ethyl 4-(6-indazolamino)quinaldine-3-carboxylate 6-Aminoindazole (1.6 g.) and ethyl 4- chloroquinaldine-3-carboxylate (3.0 g.) were combined and gently warmed. The mobile reaction mixture solidified. This was dissolved in hot ethanol, basified with 10% NH OH, and the product precipitated with water. Recrystallization of the product from aqueous ethanol yielded pale yellow prisms 1.5 g.: 33%), m.p. 226-7. Analysis for C H N O Calcd.: C, 69.35; H, 5.24; N, 16.18
Found C, 69.05; H, 5.30; N, 16.40
EXAMPLE 14 Ethyl 4-(4-indazolamino)-quinaldine-3-carboxylate 4.66 g. (0.035 mole) of 4-Amino-indazole was dissolved in 200 ml. of dry acetone. To this mixture was added 8.7 g. (0.035 mole) of ethyl 4-chloroquinaldine- 3-carboxy1ate and the mixture was refluxed for 24 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The ethyl 4- (4-indazolamino)-quinaldine-3-carboxylate hydrochloride was dissolved in 100 ml. of alcohol and 100 ml. of water and the pH of this mixture was adjusted to 8-9 with 10% NH OH. The compound that precipitated was collected on a Buchner funnel, washed well with water and dried overnight in vacuo. Yield 7.0 g. After two recrystallizations from ethyl acetate (charcoal), the product melted at 177-l78. Yield 3.9 g. after drying to constant weight for 2 days in vacuum oven at 100C. Analysis for C H N O,
Calcd.: C, 69.35; H, 5.24; N, 16.18
Found C, 69.05; H, 5.34; N, 16.06
EXAMPLE 1 5 Ethyl 7-chloro-4-( 6-indazolamino )-quinoline-3 carboxylate a. A mixture of 32.6 g. (0.13 mole) of ethyl 7-chloro- 4-hydroxyquinoline-3-carboxylate, 60 ml. of phosphorous oxychloride and 27 g. (0.13 mole) of phosphorous pentachloride was boiled under reflux for 2 hours and cooled. This mixture was poured slowly wwth stirring onto 1.5 Kg. of ice and 1.5 liters of NH OH keeping the mixture alkaline to phenolphthalein at all times. Stirring was continued for 2 hours and the precipitate was collected by filtration and air dried overnight. The solid was leached with several portions of boiling ether. The ether solution was dried over Na SO and concentrated in vacuo. The crystalline residue was leached with several portions of boiling petroleum ether and the residue was discarded. The petroleum ether extracts were combined, treated with charcoal (KB), concentrated until crystallization began, and then cooled. The colorless crystals that separated were collected by filtration and dried. The product, ethyl 4,7-dichloro-3- quinolinecarboxylate, was obtained in a yield of 10 g., m.p. 78-80. 1n the literature, m.p. 80-82, Edward F. Elslager and coworkers, J. Pharm. Chem., 5, 558 (1962).
b. 4.6 g. (0.035 mole) of 6-aminoindazole was dissolved in 250 ml. of dry acetone. To this mixture was added 9.5 g. (0.035 mole) of ethyl 4,7-dichloro-3- quinoline carboxylate obtained above and the mixture was refluxed for 8 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The ethyl 7-chloro-4(6- indazolamino)quinoline-3-carboxylate hydrochloride was dissolved in a mixture of alcohol and water and the pH- of this mixture was adjusted to 8-9 with 10% NH OH. The compound that precipitated was collected on a Buchner funnel, washed well with water. After two recrystallizations from ethanol and charcoal, the product melted at 208-209. After drying to constant weight for two days in a vacuum oven at yield was 4.0 g.
Analysis for C H CIN O Calcd.: C, 62.21; H, 4.12; N, 15.28 Found C, 62.09; H, 4.00; N, 15.26
EXAMPLE 16 Ethyl 4-(S-indazolamino)-quinaldine-3-carboxylate 4.65 g. (0.035 mole) of S-Aminoindazole was dissolved in 250 ml. of dry acetone. To this mixture was added 8.7 g. (0.035 mole) of ethyl 4-chloroquinaldine- 3-carboxylate and the mixture was refluxed for 8 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. Ethyl 4-(5- indazolamino )-quinaldine-3-carboxylate hydrochloride was dissolved in 500 ml. of 50 percent alcohol and the pH of this mixture was adjusted to 8-9 with 10% NH,OH. The compound that precipitated was collected on a Buchner funnel and washed well with water and dried overnight in vacuo. Alter two recrystallizations from ethyl acetate, the product melted at 225-226. Yield 3.6 g. (after drying to constant weight for three days in vacuum oven at 100). Analysis for C,,H,,N 0,
Calcd.: C, 69.35; H, 5.24; N, 16.18
Found C, 69.41; H, 5.34; N, 16.08
EXAMPLE l7 Ethyl 4-( 7-indazolamino)-quinaldine-3-carboxylate 9.3 g. (0.07 mole) of 7-amino-indazole was dissolved in 500 ml. of dry acetone. To this mixture was added 17.4 g. (0.07 mole) of ethyl 4-chloroquinaldine-3- carboxylate and the mixture was refluxed for 21 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The ethyl 4-(7- indazolamino)-quinaldine-3-carboxylate hydrochloride was dissolved in 500 ml. of 50 percent alcohol and the pH of this mixture was adjusted to 8-9 with 10% Nl-LOH. The compound that precipitated was collected on a Buchner funnel and washed well with water. After two recrystallizations from ethanol the product melted at l97198; Yield 6.5 g. (after drying to constant weight for 2 days in vacuum oven at 80-90). Analysis for C 11 N 0,
Calcd.: C, 69.35; H, 5.24; N, 16.18
Found C, 69.24; H, 5.29; N, 16.28
EXAMPLE 18 Ethyl 7-trifluoromethyl-4-(6-indazolamino)-quinoline- 3-carboxylate a. A mixture of ethyl 4-hydroxy-7- trifluoromethylquinoline-3-carboxylate, 60 ml. of phosphorous oxychloride and 15 g. of phosphorous pentachloride was heated under reflux for 8 hours and cooled. This mixture was poured slowly with stirring into 1.5 Kg. of ice and made basic pH 10-11 with 10N NaOH. Stirring was continued for additional 2 hours and a gummy precipitate was obtained which crystallized upon standing. The crystalline compound was filtered and washed well with water. The solid was leached with 300 ml. of ether. The ether solution was dried over Na SO, and concentrated in vacuo. With the addition of petroleum ether, the compound, ethyl 4- chloro-7-trifluoromethylquinoline-3-carboxylate, crystallized. lt melted at 62-64. Yield: 4.6 g. Analysis for C H ClF N Calcd.: C, 51.41; H, 2.99; N, 4.61
Found C, 51.46; H, 2.99; N, 4.81
b. 1.79 g. (0.0133 mole) of 6-Aminoindazole was dissolved in 100 ml. of dry acetone. To this mixture was added 4.1 g (0.0133 mole) of ethyl 4-chloro-7- trifluoromethyl quinoline-3-carboxylate obtained above and the mixture was refluxed for 7 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The ethyl 7- trifluoromethyl-4-(6-indazolamino)-quinoline-3- carboxylate hydrochloride was dissolved in a mixture of alcohol and water and the pH of this mixture was adjusted to 8-9 with 10% NH OH. The compound that precipitated was collected on a Buchner funnel and washed well with water. After recrystallization from a mixture of cyclohexane and ether, the product melted at 158-l60. Yield 2.4 g. Analysis for C H F N O,
Calcd.: C, 60.00; H, 3.78; N, 13.99
Found C, 59.96; H, 3.80; N, 13.78
EXAMPLE l9 4-(6-lndazolamino)-quina.ldine-3carboxylic acid Methyl acetoacetate (315 g.), isatoic anhydride (300 g.), sodium hydroxide (5 g.) and dioxane (750 ml.) were mixed together with moderate stirring and the mixture was refluxed for a period of 24 hours during which time carbon dioxide was evolved. The reaction mixture was cooled and the product precipitated. The compound, methyl-4-hydroxyquinaldinc-3-carboxylate was filered and washed with ether. Yield: 135 g., m.p. 237-238.
b. 135 g. of methyl 4-hydroxyquinaldine-3- carboxylate obtained above and 450 ml. of phosphorous oxychloride were refluxed for a period of 2 hours. The excess POCl was removed in vacuo to give a syrupy residue. This was cooled, 200 ml. of ethanol was added and the mixture was stirred for 30 minutes. The solid was filtered and dissolved in 500 ml. of water. The pH of this mixture was adjusted to 8-9 with 10% NH,OH. The reaction mixture was extracted with ether The ether extract was washed with water, dried over MgSO, and concentrated in vacuo to give a solid, methyl 4-chloroquinaldine-3-carboxylate, melting at 58-60. Yield 78.8 g.
c. 26.6 g. of 6-Aminoindazole were dissolved in 850 ml. of dry acetone and to this mixture was added 47 g. (0.2 mole) of methyl 4-chloroquinaldine-3-carboxylate obtained above. The mixture was refluxed with stirring for 6 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The salt (methyl 4-(6-indaz0lamino)-quinaldine-3- carboxylate hydrochloride) was dissolved in 400 ml. of 50 percent alcohol and the pH of this mixture was adjusted to 8-9 with 10% NI-LOH. The compound that precipitated was collected on a Buchner funnel and washed well with water. After two recrystallizations from ethanol the product, methyl 4-(6-indazolamino)- quinaldine-3-carboxylate melted at 232233. Yield 30 g.
d. 11 g. (0.033 mole) of methyl 4-(6-indazolamino)- quinaldine-B-carboxylate obtained above was suspended in 100 ml. of 3N NaOH and the reaction mixture was refluxed for a period of 4 hours. The reaction mixture was cooled and 100 ml. of water was added. The aqueous mixture was extracted with ethyl acetate (to remove unreacted ester). The water solution was made acid to pH 3.8 with 3N HCl. The compound precipitated. The precipitate was collected and washed well with water. After recrystallization from 600 ml. of methanol using charcoal, the compound, 4-( 6- indazolamino)quinaldine-3-carboxylic acid, melted at 273-275. Yield: 5.0 g. The same compound was obtained when methyl 4-( 6-indazolamino)-quina1dine-3- carboxylate was hydrolyzed with Lil in pyridine solution. Analysis for C;gH N402 Calcd.: C, 67.92; H, 4.43; N, 17.60
Found C, 67.90; H, 4.23; N, 17.42
EXAMPLE 20 pH of this mixture was adjusted to 10-11 with 3N NaOH. The compound that precipitated was collected on a Buchner funnel and washed well with water. Re-
crystallization from ethanol and charcoal afl'orded a compound which melted at 243245. Yield: 10.4 g. Analysis for C,,,H,,,N O
Calcd.: C, 68.66; H, 4.85; N, 16.86
Found C, 68.40; H, 4.95; N, 16.74
EXAMPLE 21 Methyl 4-(6-indazolamino)-quinaldine-3-carboxylate 26.6 g. of 6-aminoindazole were dissolved in 850 ml. of dry acetone and to this mixture was added 47 g. (0.2 mole) of methyl 4-chloroquinaldine-3-ca.rboxylate. The mixture was refluxed with stirring for 6 hours. The reaction mixture was cooled and the hydrochloride salt of the product was collected. The salt [methyl 4-(6- indazolamino)-quinaldine-3-carboxylate hydrochloride] was dissolved in 400 ml. of 50 percent alcohol and the pH of this mixture was adjusted to 8-9 with 10% NH OH. Thp compound that precipitated was collected on a Buchner funnel and washed well with water. After two recrystallizations from methanol, the product melted at 232-233. Yield: 30 g. Analysis for C H N O Calcd.: C, 68.66; H, 4.85; N, 16.86
Found C, 68.71; H, 5.05; N, 16.93
EXAMPLE 22 7-Chloro-4-(6-indazolamino)-quinoline-3-carboxylic acid A mixture of 3.5 g of ethyl 7-chloro-4-(6- indazolamino)-quinoline-3-carboxylate and 25 ml. of 3N sodium hydroxide was heated under reflux for 3 hours. During this time a yellow solution was obtained, which was then diluted with 75 ml. of water and acidified to pH 6. The solid which precipitated was collected by filtration and then suspended in hot methanol and reflltered to yield a yellow solid, m.p. 289; Yield: 2.4
Analysis for C,,H,,C1N,O I
Calcd.: C, 60.27; H, 3.27; N, 16.54; C1, 10.47 Found C, 60.10; H, 3.43; N, 16.27; Cl, 10.47
EXAMPLE 23 Ethyl 2-phenyl-4-(5-indazolamino)-quinoline-3- carboxylate a. A mixture of 138 g. (0.82 mole) of isatoic anhydride, 253.8 g. (1.31 mole) of ethyl benzoylacetate, 4.6 g. of sodium hydroxide and 530 ml. of p-dioxane were heated under reflux for 8 hours. The solution was cooled; the product, ethyl 2-pheyl-4-hydroxyquinoline- 3-carboxylate, was collected and washed with ether. Yield: 48.5 g., m.p. 252-255.
b. A mixture of 48.5 g. (0.164 mole) of ethyl 2- phenyl-4-hydroxyquinoline-3-carboxylate, obtained above, and 130 ml. of phosphorous oxychloride was heated under reflux for 3 )ihours. The excess phosphorus oxychloride was removed by distillation under reduced pressure, leaving a reddish gum which was dissolved in ethanol. The solution was basified with 3N NaOH and diluted with water. The aqueous solution was extracted with ether and the ethereal extracts were dried over sodium sulfate and evaporated to dryness yielding an oil which crystallized on trituration with petroleum ether. Yield: 40.2 g., m.p. 6265.
c. To a solution of 11.6 g. (0.864 mole) of 5- aminoindazole, dissolved in dry acetone, was added 35.2 g. (0.864 mole) of ethyl 2-phenyl-4- chloroquinoline-3-carboxylate, obtained above The reaction mixture was heated under reflux for 8 hours, and the hydrochloride salt of the product was collected. A suspension of the ethyl 2-phenyl-4-(5-indazolamino)- quinoline-3-carboxylate hydrochloride in a mixture of 150 ml. of water and 15 ml. of ethanol and was basified with 3N NaOH. The compound that precipitated was collected and washed well with water. After two recrystallizations from ethanol, using charcoal, the product melted at 220222. Yield: 5.6 g. Analysis for C H N O Calcd.: C, 73.50; H, 4.94; N, 13.72
Found C, 73.27; H, 4.87; N, 13.76
EXAMPLE 24 Methyl 4-(3-chloro-6-indazolamino)-quinaldine-3- carboxylate a. To a solution of ferrous sulfate (326 g.) in water (400 ml.) was added to a hot solution of 3-chloro-6- nitroindazole (39.4 g., 0.2 mole) in ethanol (410 ml.); concentrated NH Ol-l was then added (246 ml.). This mixture was heated under reflux on the steam bath for 20 minutes, NH,OH (400 ml.) was again added and heating was continued for an additional 20 minutes. The suspension was filtered hot, the salts were washed several times with boiling ethanol, the washings and filtrate were evaporated to dryness in vacuo; the residue was dissolved in ethyl acetate, the solution was dried over Na SO charcoaled and evaporated to dryness, m.p. l77l82; Yield; 24.3 g. (Lit: m.p. 185, Robert R. Davies, J. Chem. Soc. 1955, 2,414).
b. 3-Chloro-6-aminoindazole, obtained above, (13.5 g., 0.08 moles) was dissolved in dry acetone (100 ml.) and then methyl 4-chloroquinaldine-3-carboxylate (17.7 g., 0.08 mole) was added. The resulting solution was boiled under reflux (oil bath, 100) for 8 hours, precipitating methyl 4-(3-chloro-6-indazolamino)- quinaldine-3-carboxylate hydrochloride. The hydrochloride salt was collected, suspended in ethanol, water (400 ml., 1:3), the suspension was basified with 3N NaOH and diluted with water. The precipitate was collected, and washed with water. After two recrystallizations from a mixture of ethyl acetate and methanol with charcoal treatment, the product melted at 258. Yield: 15.1 g.
Calcd.: C, 62.21; H, 4.12; N, 15.28; C], 9.67 Found C, 61.80; H, 3.92; N, 15.12; Cl, 9.63
EXAMPLE 25 Ethyl 4-(S-indazolamino)-quinoline-2-carboxylate S-Amino-indazole (9.2 g., 0.069 mole) was dissolved in dry acetone (125 ml.) with heating and stirring.
6 recrystallized from ethanol. Yield: 1.8 g., m.p. 258.
Analysis for C,,H N O,
Calcd.: C, 68.66; H, 4.85; N, 16.86 Found C, 68.07; H, 4.90; N, 16.70
EXAMPLE 26 7-Chloro-4-(6-indazolamino)-quinoline 0.5 g. of 7-Chloro-4-(6-indazolamino)-quinoline-3- carboxylic acid was suspended in 50 ml. of diphenylether and the mixture was heated under reflux for 70 minutes (reflux temperature approximately 257259). The reaction mixture was cooled to 80 and filtered. The crystalline compound was washed well with ether and was obtained in a yield of 0.35 g. After recrystallization from ethanol, the compound melted at 251-253. The IR spectrum confirmed the structure of the product as set out in Example 1 supra.
EXAMPLE 27 4-(2-methyl-6-indazolamino)-quinaldine 4-Ch1oroquinaldine (4.71 g., 0.0265 moles) was added to a solution of 2-methyl-6-aminoindazole (3.9 g., 0.0265 moles) in hydrochloric acid (3N, 80 ml.) and the resulting solution was heated under reflux for 16 hours. A yellow crystalline solid was precipitated on cooling. This solid was dissolved in dilute ethanol (20% 500 ml.) and the solution was made basic with 3N sodium hydroxide (pl-l 9-11) precipitating a white crystalline product which was collected, washed well with water, recrystallized first from hot ethanol and then recrystallized twice from ethyl acetate/ethanol. Yield: 1.45 g., m.p. 255257. Analysis for C l-l N Calcd.: C, 74.97; H, 5.59; N, 19.44
Found C, 74.57; H, 5.66; N, 19.80
Using the procedure described above, 4-(1-methyl-6- indazolamino)-quinaldine was obtained in a yield of 50-51%, m.p. 330-331(dec.).
EXAMPLE 28 Ethyl 4-hydroxy-7-methylquinoline-3-carboxylate m-Toluidine (53.6 g., 0.5 moles) and diethyl ethoxymethylenemalonate (108.1 g., 0.5 moles) were mixed together and placed in a dessicator under vacuum over anhydrous calcium chloride. (water uptake of 4.9 g.) for 7 days. The resulting crotonate was added to refluxing phenyl ether (500 ml.), the solutionwas heated under reflux for 10 minutes, filtered at 70 and the product was triturated twice in ether (1 liter). There was obtained a yield of 6.1 g., m.p. 275-280 dec.
EXAMPLE 29 Ethyl 4-(5-indazolamino)-7-methylquinoline-3- carboxylate A solution of ethyl 4-hydroxy-7-methylquinoline-3- carboxylate (6.1 g., 0.0264 moles) was heatedunder reflux in phosphorous oxychloride (35 ml.) for 1 hour. The reaction mixture was then poured into cracked ice about 1 liter), the pH was adjusted to 9-11 with 3N sodium hydroxide precipitating a white crystalline compound which was filtered and washed with water. A solution of the product in ether was dried over sodium sulfate/magnesium sulfate, charcoaled and evaporated to dryness yielding a solid on cooling with a melting point of 40-42 (5.7 g.).
'S-Aminoindazole (3.28 g., 0.0247 moles) was dissolved in dry acetone (100 ml.) with heating and stirring. Ethyl 4-chloro-7-methylquinoline-3-carboxylate (5.7 g., 0.0247 moles) obtained above, was added and resulting solution was heated under reflux (oil bath 90) for- 8 hours precipitating a yellow crystalline solid.
The crystals were collected, dissolved in dilute alcohol (200 ml., 50%) and the precipitate was adjusted to a pH of 9-1 1 with 3N sodium hydroxide. 600 ml Of water was added and the resulting precipitate was collected and washed well with water. The compound was first recrystallized from alcohol and after two additional recrystallizations from ethyl acetate, the product melted at 239-240; yield of 2.2 g. Analysis for G l-1 N 0 Calcd.: C, 69.34; H, 5.24; N, 16.17
Found C, 69.00; H, 5.52; N, 15.70
EXAMPLE 30 l-Methyl-4-(b 6-indazolimino)-1 ,4-dihydro-quinaldine A mixture of 4-chloroquinaldine (33.7 g., 0.192 mole) and methyliodide (79 g.) was boiled under reflux in acetonitrile (250 ml.) for 3 hours. T he reaction mixture was cooled, the crystalline salt collected on a Buchner funnel and washed with acetonitrile (1 X 55 ml.). The product, 1-methyl-4-chloroquinaldinium iodide, melted at 226-228C. dec; yield 16.4 g. l-Methyl-4-chloro-quinaldinium iodide 10 g., 0.032 mole) was added to a solution of 6-aminoindazole (4.26 g., 0.032 mole) dissolved in 28 EtOH (500 ml.) and this mixture was boiled under reflux for 20 hours. The reaction mixture was cooled and filtered yielding a yellow solid which was suspended in water/EtOl-l (3:1, 400 ml.); the suspension was basified wth 3N NaOH to PH 8-9. The resulting crystalline compound was collected on a Buchner funnel, washed well with water, (5 X 100 ml.), dissolved in hot methanol, charcoaled twice and then recrystallized from EtOH/MeOl-l 1:1), yielding a yellow crystalline solid (1.8 g., m.p. 299-301).
EXAMPLE 31 7-Chloro-1 -methyl-4-(6-indazolimino)-1 ,4-dihydroquinoline A mixture of 4,7-dichloroquinoline (32.5 g., 0.17
mole) and methyl iodide (42. g., 0.51 mole) was boiled under reflux in 250 ml. of acetonitrile for a period of 2.5 hours. The reaction mixture was cooled and the crystalline salt collected on a Buchner funnel and washed with acetonitrile. The product, 4,7-dichloro-1- methyl-quinoliniumiodide, melted at 258259. Yield: 31.7 g.
The aforesaid product (10 g., 0.031 mole) was added to a solution of G-aminoindazole (4.1 g., 0.031 mole) dissolved in 500 m1. of ethanol and this mixture was boiled under reflux for a period of 24 hours. The reaction mixture was cooled and filtered yielding a solid which was suspended in 300 ml. of 50% ethanol and was basifled with 3N NaOl-l to pH 8-9. The resulting crystalline compound was collected on a Buchner funnel and washed well with water. Afler recrystallization from a mixture of ethanol methanol 1:1 the desired compound melted at 266-267. Yield: 2.8 g. Analysis for C, ld,,C1N
Calcd.: C, 66.12; H, 4.25; N, 18.14
Found C, 66.09; H, 4.54; N, 18.23
EXAMPLE 32 4-( 1-Methyl-5-indazolamino)-quinaldine a. l and 2-Methyl-5-nitroindazoles were prepared and separated as described by I. Barclay et al., J. Chem. Soc., 1941,113.
b. To a solution of 26.4 g of S-nitro-l-methylindazole (0.208 mole) in 1,000 ml of ethanol was added a solution of ferrous sulfate 430 g in 650 ml of hot water, followed by the addition of 500 ml of concentrated ammonium hydroxide. The resulting mixture was heated on a steam bath for 3 hours and 320 ml of concentrated ammonium hydroxide was added at 30 minute intervals. The reaction mixture was filtered hot and the residue was washed with 2,000 ml of hot methanol. The filtrate and the washings were combined and concentrated in vacuo. The residue was extracted with 1,500 ml (6 X 250 ml) of hot ethyl acetate and the solution was dried over Na SO and the solvent was removed under reduced pressure. After recrystallization from water the obtained S-amino-l-methylindazole melted at 151-153. Yield 12.7 g.
c. A mixture of S-amino-l-methylindazole (12.6 g: 0.855 mole) and 4-chloroquinaldine 15.2 g: 0.855 mole) was dissolved in 375 ml of 3 HCl and the solution was heated under reflux for 8 hours. The reaction mixture was reduced to circa 200 ml under reduced pressure and the hydrochloride salt of the product was collected. The salt was suspended in a mixture of 160 ml of water and 40 ml of ethanol and basified with 3 N NaOH solution. An additional 200 ml of water was added to ensure complete precipitation of the product, which was collected by filtration. After recrystallization from the ethyl acetate the obtained 4-(1-methyl- 5-indazolamino)-quinaldine melted at 213-214. Yield 3.4 g.
Analysis for C H N Calcd.: C, 74.97; H, 5.59; N, 19.44 Found C, 74.71; H, 5.46; N, 19.60
EXAMPLE 33 Ethyl 7-chloro-4-(6-indazolamino)-quinaldine-3- carboxylate a. A mixture of 63.8 g of 3-ch1oroaniline and 101.6
g of diethylacetylmalonate was stored in vacuo in a dessicator over anhydrous CaCl, for 10 days. 7.0 g of water was taken up. The resulting crotonate was poured into 500 ml of refluxing diphenyl ether and the mixture was heated under reflux for 40 minutes. Upon cooling to 70C the precipitate was collected by filtration and purified by trituration in a mixture of ether and hexane. After recrystallization from ethanol the obtained ethyl 7-chloro-4-hydroxy-quinaldine-S- carboxylate meltedat 297-300C. Yield 22.7 g.
A mixture of the above product and the isomeric ethyl 5-chloro-4-hydroxyquinaldine-3-carboxylate has been described previously by B.P. Bangdivalo and CM. Desai, J. Ind. Chem. Soc., 31, 555 (1954) utilizing a different procedure.
b. A mixture of 22.7 g of ethyl 7-chloro-4- hydroxyquinaldine-3-carboxylate and 100 m1 of phosphorous oxychloride was heated under reflux for 3 hours. The phosphorous oxychloride was then removed by distillation under reduced pressure. The reaction mixing was cooled and 75 ml of ethanol was added with stirring. The hydrochloride salt which precipitated was collected by filtration and dissolved in 500 ml of dilute ethanol (80 percent). The solution was rendered basic with 3 N NaOl-l. Additional water was added to ensure complete precipitation of the product, which was collected by filtration. The obtained ethyl 4,7-dichloroquinaldine-3-carboxylate melted at 58-61C. Yield 9.8 g.
c. G-Aminoindazole (4.6 g., 0.0345 mole) was dissolved in dry acetone ml) with heating and stirring; ethyl 4,7-dichloroquinaldine-3-carboxylate (9.8 g, 0.0345 mole) dissolved in dry acetone (100 cc) was added to the solution of aminoindazole and the mixture was boiled under reflux for 8 hours precipitating the hydrochloride. After two recrystallizations from dilute alcohol the hydrochloride of ethyl 7-chloro-4-(6 indazolamino)-quinaldine-3-carboxylate melted at 261-263. Yield 4.3 g.
d. The above salt was suspended in dilute alcohol (50%, 250 cc), the solution was basified with Nl-LOl-l and diluted with water. The precipitate was collected and washed well with water. After two recrystallizations from dilute alcohol the title compound was obtained which melted at 214-215. Yield 3.1 g. Analysis for C I-I CIN O Calcd.: C, 63.07; H, 4.50; N, 14.52
Found C, 62.87; H, 4.64; N, 14.86
EXAMPLE 34 Ethyl 4-(2'-methyl-6-indazolamino)quinaldine-3- carboxylate a. A mixture of 600 g (0.611 mole) of 6- nitroindazole, 34.25 g (0.611 mole) of potassium hydroxide, 173.8 g (1.222 mole) of methyl iodide and 800 ml of methanol were heated under reflux for 4 hours. The reaction mixture was poured into 2.5 1 of ice water and the resulting precipitate collected by filtration. The dried precipitate 2-methyl-6-nitroindazole was recrystallized from methanol and melted at l58160C. (Lit. Barclay, J. Chem. Soc. 113 (1941) reported m.p. 159-160C.).
b. 21.1 g, (0.1184 mole) of 2-methyl-6-nitroindazole was dissolved in 450 ml of EtOl-l with heating and stirring. g of FeSO dissolved in 300 ml of hot water was added to the indazole solution followed immediately by the addition of 275 ml of cone. NH,OH. The resulting mixture was heated on the steam bath for 3 hours and 275 ml of concentrated Nl-LOH was added at 30 minute intervals. The reaction mixture was filtered hot; the filter cake was dried overnight in vacuo; the filtrate was concentrated to dryness in vacuo. The filter cake and filtrate residues were combined, extracted with 1,000 m1 (4 X 250 ml) of hot ethyl acetate and the solution was dried over Na,S O /MgS0,, and the solvent removed under reduced pressure. After two recrystallizations from water, the obtained 2-methyl-6- amino-indazole melted at 82-858C. Yield 4.6 g.
c. To a solution of 2-methyl-6-aminoindazole (4.6 g:
0.03122 mole) in dry acetone (75 ml) was added a solution of ethyl 4-chloroquinaldine-3-carboxylate (7.8 g: 0.03122 mole) dry acetone (25 ml) and the resulting mixture was heated under reflux for 8 hours precipitating the hydrochloride salt of ethyl 4-(2-methyl-6- indazolamino)-quina.ldine-3-carboxylate.
This salt was collected and dissolved in 10 percent dil. EtOl-l (500 ml); the solution was cooled and basified with cone. NH OH and diluted with 11,0; the precipitate was collected by filtration and washed well with P1 0.
After two recrystallizations from dilute EtOl-l, the title compound melted at 122-124C. Yield 4.1 g. Analysis for C, H, N,O,
Calcd.: C, 69.98; H, 5.59; N, 15.54 9
Found C, 70.26; H, 5.52; N, 15.88
EXAMPLE 35 Ethyl 4-(fi-indazolamino)-quinaldine-3-carboxylate-1- oxide a. Ethyl 4-chloroquinaldine-3-carboxylate (23.4 g: 0.175 mole) was dissolved in CHCl (250 ml). m- Chloroperbenzoic acid (29.4 g: 0.175 mole) was dissolved in CHCl (250 ml) and added to the quinaldine solution; the resulting mixture was allowed to stand at room temperature for 72 hours.
The reaction mixture was extracted with 5% Na CO (4 X 150 ml), then washed with H (3 X 200 ml). The chloroform solution was dried over K CO and the solvent removed under reduced pressure to yield a residue which crystallized on cooling, and trituration with petroleum ether. Yield 21 g., m.p. 127-129C. The obtained compound was ethyl 4-(6-indazolamino)- quinaldine-3-carboxylate-l-oxide.
b. 6-Aminoindazole (10.01 g.: 0.0753 mole) was dissolved in EtOH (310 ml) and H 0 (45 ml). Ethyl 4- chloroquinaldine-3-carboxylate-l-oxide (20 g.; 0.0753 mole) dissolved in EtOH (50 ml) was added to the indazole solution with drops of concentrated l-iCl. The resulting mixture was refluxed for 24 hours and concentrated in vacuo to a residual solid. This solid was suspended in H O, the suspension was basified with concentrated Nl-1 0l-1, and the resulting precipitate was collected and washed with 11 0.
After two recrystallizations from acetone (1 X charcoal) the title compound melted at 239-240C (dec.). Yield 6.5 g.
EXAMPLE 36 7-Chloro-4-(6-indazolamino)-quinoline-l-oxide a. 4,7-Dichloroquinoline (99 g, 0.5 mole) was dissolved in CHCl (300 ml) at room temperature. m- Chloroperbenzoic acid (80%, 101.4 g, 0.5 mole) suspended in Cl-lCl; (1 liter) was added to the quinoline solution. The resulting mixture was allowed to stand at room temperature for 48 hours. The Cl-lCl, solution was washed with 10% Na,CO solution (3 X 500 ml), then with H 0 (3 X 1 liter), dried over K,CO, and concentrated in vacuo.
Recrystallization from EtOH yielded 37.7 g of 4,7- dichloro-quinoline-l-oxide, m.p. 162-l64C. Lit. Ref: E.F. Elslager et al., .1. Med Chem., 1, 6 1964). Reported m.p. 165-l66C.
b. 6-Aminoindazole (13.7 g, 0.096 mole) was dissolved in EtOH (400 ml) and 11,0 (60 ml). 4,!- Dichloroquinoline-l-oxide (20.6 g, 0.096 mole) suspended in cold EtOH (200 ml) was added to the indazole solution. After the addition of 6 drops of concentrated HCl, the mixture was heated under reflux for 24 hours. The solvent was concentrated in vacuo and the residue was suspended in 11,0 (500 ml). The suspension was stirred with cooling and filtered. The precipitate was suspended in dilute EtOH (20%, 400 m1) and was basified with cone. NH OH, diluted well with 11,0 to give precipitate which was collected.
After two recrystallizations from dilute MeOl-l (1 X charcoal), the title compound melted at 281-283C. Yield 5.4 g.
Analysis for C H CIN O Calcd.: C, 61.84; H, 3.57; N, 18.03 Found C, 61.81; H, 3.46; N, 18.31
EXAMPLE 37 7-Chloro-4 (6-indazolamino)-quinoline fonate 6-Aminoindazole (13.1 g; 0.1 mole) was dissolved in acetonitrile (500 ml) and concentrated hydrochloric acid (1.0 ml) was added. The precipitated hydrochloric salt was dissolved by the addition of dimethylformamide to the mixture. 4,7-Dichloroquinoline (19.8 g; 0.1 mole) was added and the solution was refluxed for 4 hrs. The reaction mixture was cooled to room temperature and the product was filtered off and suspended in ethanol (500 ml) with warming. Concentrated aqueous ammonia was added to pH 9 followed by water (2.0 l). The mixture was cooled and the free base filtered off. This material was vacuum dried (27.6 g) and suspended in ethanol (500 m1) and methanesulfonic acid (8.85 g; 1 equiv.) was added. The solution was evaporated to dryness and the residue was recrystallized from ethanol to give 28.6 g of the methanesulfonate salt. m.p. 253(dec).
EXAMPLE 38 4-(6-lndazolamino)-2-trifluoromethylquinoline Dimethane-sulfonate a. 4-1-1ydroxy-2-trifluoromethylquinoline was prepared by the method of A. S. Dey and M. M. Joulie', .1. 'Heterocyclic Chem., 2, 113 (1965), [2- trifluoromethy1-4-quinolinolsgeneral method a.].
b. 4-Chloro-2-trifluoromethylquinoline was prepared by the method of H. R. Snyder et al, J. Amer. Chem. Soc., 69, 371 (1947). A mixture of phosphorous pentachloride (16.4 g) and phosphorous oxychloride (18.4 g) was heated to 4-hydroxy-2-trif1uoromethylquinoline (16.0 g) was added, and the solution was refluxed for 40 minutes. The solution was evaporated under vacuum and the residue was added to ice water ml). The resultant precipitate was filtered off and recrystallized from aqueous ethanol to give 9.4 g of the 4-chlorocompound.
c. 6-Aminoindazole (9.4 g, 0.033 mole) was dissolved in acetonitrile ml) and concentrated hydrochloric acid (0.33 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (80 ml) to the mixture. 4-Hydroxy- Z-trifluoromethylquinoline (9.4 g; 033 mole) was added and the reaction mixture refluxed for 3% hrs., then cooled to room temperature. The solution was evaporated under vacuum and the residue dissolved in ethanol (400 ml). Concentrated aqueous ammonia was added to pH 9. The mixture was cooled and the free base (1.2 g) was filtered off and vacuum dried. This material was suspended in ethanol (50 ml) and methanesulfonic acid (700 mg, 2 equiv.) was added. The resulting solution was evaporated to dryness and the residue recrystallized from ethanol togive 350 mg of the methanesulfonate. m.p. 2 l8-220.
EXAMPLE 39 2-(4-Chloropheny1)4-(6-indazolamino)quinoline Methanesulfonate l-lemi-ethanol Solvate 6-Aminoindazole (0.66 g, 0.005 mole) was dissolved in acetonitrile (25 ml) and concentrated hydrochloric acid (0.05 ml) was added. The hydrochloride salt was dissolved by the addition of dimethylformarnide (12.5 ml). 4-Chloro-2-(4-ch1orophenyl)quinoline [1.3 g,
Methanesul- 0.005 mole; prepared by the method of RM. Peck, R.K. Preston, and HJ. Creech, J. Amer. Chem. Soc., 81, 3984 (1959)] was added and the solution was refluxed for 3 hr. After cooling, the hydrochloride salt of the product was filtered off and dissolved in 70 percent aqueous ethanol (50 ml). Concentrated aqueous ammonia was added to pH 8; the precipitated free base was filtered off and vacuum dried. This material was suspended in ethanol (25 ml) and methanesulfonic acid (1 equivalent) was added. The solution was evaporated and the residue recrystallized four times from ethanol to give 0.8 g of the hemi-ethanol solvate. The presence of the ethanol was confirmed by NMR; the solvate was stable to prolonged vacuum drying. The compound decomposed at 233.
EXAMPLE 40 7-Chloro-4-(6-indazolamino)quinaldine Methanesulfonate 6-Aminoindazole (1.62 g; 0.012 mole) was dissolved in acetonitrile (61 ml) and concentrated hydrochloric acid (0.12 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (30 ml). 4,7-Dichloroquinaldine [2.6 g, 0.012 mol., prepared by the method of A.1(. Sen and UP. Basu, J. Indian Chem. Soc., 34, 833 (1957)] was added and the solution refluxed for 3 hrs. After cooling, the hydrochloride was filtered off and dissolved in ethanol (100 ml) and water (20 ml). Concentrated aqueous ammonia was added to pH 8, and after refrigeration, the free base was filtered off and vacuum dried (2.0 g). This material was suspended in ethanol (100 ml) and methanesulfonic acid (0.62 g; 1 equiv.) was added. The solution was evaporated and the residue recrystallized from ethanol to give 1.8 g of the methanesulfonate, m.p. 256258.
EXAMPLE 41 4-(6-1ndazolamino)-6-methoxyquinoline Methanesul fonate 6-Aminoindazole (0.66 g; 0.005 mole) was dissolved in acetonitrile (25 ml) and concentrated hydrochloric acid (0.05 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide 12.5 ml) to the mixture, 4-ch1oro-6- methoxyquinoline (1 g; 0.005 mole) was added and the solution was refluxed for 3 hrs. The reaction mixture was cooled, and the product was filtered off then suspended in ethanol (100 ml) with warming. Concentrated aqueous ammonia was added to pH 9 and after refrigeration the free base was filtered off. This material was vacuum dried then suspended in ethanol (50 ml). Methanesulfonic acid (1 equivalent) was added and the resulting solution evaporated to dryness. Recrystallization of the residue from ethanol/ethyl acetate gave the methanesulfonate lg), m.p. 258-260 dec.
EXAMPLE 42 6-Chloro-4-(6-1ndazolamino)-2-phenylquinoline Methanesulfonate One Third Hydrate 6-Aminoindazole (533 mg; 4 m mole) was dissolved in acetonitrile (20 ml) and concentrated hydrochloric acid (0.04 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (10 ml) to the mixture. 4,6-Dichloro-2- phenylquinoline (1.1 g; 4 m mole) was added and the reaction mixture refluxed for 3% hr. then cooled to room temperature. The crystalline material was filtered off and dissolved in a mixture of water (7 ml) and ethanol (33 ml). Concentrated aqueous ammonia was added to pH 9. The mixture was cooled and the free base (1.15 g) was filtered off and vacuum dried. This material was suspended in ethanol (25 ml) and methanesulfonic acid (310 mg) was added. The resulting solution was evaporated to dryness and the residue recrystallized from ethanol/ethyl acetate to give the methanesulfonate, m.p. 290-295 dec.
EXAMPLE 43 4-(6-Indazolarnino)quinoline Methanesulfonate 6-Aminoindazole (4.0 g, 0.03 mole) was dissolved in acetonitrile (150 ml) and concentrated hydrochloric acid (0.3 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylfonnamide ml) to the mixture. 4-Chloroquinoline (4.91 g, 0.03 mole) was added and the reaction mixture was refluxed for 2 hrs. and cooled to room temperature. The crystalline material was filtered off and then dissolved in a mixture of 2B ethanol (100 ml) and water (5 ml) with warming. Concentrated ammonia was added to pH 8, which precipitated the free base. After refrigeration the product was filtered off (3.2 g), and suspended in 2B ethanol (70 ml). Methanesulfonic acid (1.2 g) was added and the resulting solution evaporated to dryness. Recrystallization from ethanol/ethyl acetate gave the methanesulfonate salt (2.6 g), m.p. 224-227.
EXAMPLE 44 4-(6-lndazolamino)-2-phenylquino1ine Methanesulfonate 7 grams (.0208 moles) of 4-(6-indazolamino)-2- phenylquinoline (Ex. 7) was partially dissolved in 100 ml hot ethanol. With the addition of 2 g (0.0208 mole) methanesulfonic acid the solution became homogeneous. Thesolvent was removed under reduced pressure, and the product was recrystallized twice from ethanol/ether to give 6 grams (67 percent) m.p. 3053 10 dec.
EXAMPLE 45 4-(6-lndazolamino )-7-methyl-2-phenylquinoline Methanesulfonate I a. 4-Chloro-7-methyl-2-phenylquinoline was prepared by the method of B.P. Bangdiwala and CM. Desai, J. Indian Chem. Soc., 31, 43 (1954), m.p. 82.
b. 6-Aminoindazole (0.85 g) was dissolved in acetonitrile (35 ml) and concentrated hydrochloric acid (0.07 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (17.5 ml). 4-Chloro-7-methyl-2-phenylquinoline 1.7 g) was added and the reaction mixture was refluxed for 3% hr. The reaction mixture was cooled to room temperature and the crystalline product filtered off, and dissolved in ethanol ml). Concentrated aqueous ammonia was added to pH 8 and the free base was precipitated by the addition of water (200 ml). The free base was suspended in ethanol (50 ml) and methanesulfonic acid (1 equivalent) was added. The solution was evaporated and the residue recrystallized from ethanol to give 1.4 g. of the monomethanesulfonate, m.p. 278-9.
EXAMPLE 46 4-(6-lndazolamino)-6-methoxy-2-phenylquinoline Methane-sulfonate 6-Aminoindazole (3.17 g; 23.8 mM) was dissolved in acetonitrile (125 ml) and concentrated hydrochloric acid (0.24 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (60 ml) to the mixture. 4-Chloro-6-methoxy-2- phenylquinoline (6.4 g; 23.8 mM) [prepared according to the method of B.P. Bangdiwala and C.M. Desai, Jour. Indian Chem. Soc., 31, 43 No. 1 (1954)] was added and the reaction mixture refluxed for 3 hrs. and cooled to room temperature. The precipitated material was suspended in hot ethanol (100 ml) and. concentrated ammonium hydroxide (20 ml) was added to give a clear solution. The free base precipitated on. standing at room temperature (6.6 g) and was dissolved in hot ethanol (100 ml) by the addition of methanesulfonic acid (1.9 g; 1.1 eq). The methanesulfonate salt on recrystallization from ethanol (2 times) gave 4.? g of the pure compound, m.p. 316318.
EXAMPLE 47 4-(6-lndazolamino)-6-hydroxy-2-phenylquinoline Methanesulfonate Monohydrate 4-( 16-Indazolamino )-6-methoxy-2-phenylquinoline hydrochloride (Ex. 46) (2.5 g) was dissolved in 48 percent hydrobromic acid (250 ml) and refluxed for 4 hrs. The crystalline material was filtered off, suspended in ethanol (150 ml) and brought into solution with concentrated ammonium hydroxide (25 ml). The free base was precipitated with water (800 ml), filtered off and dried. it then was dissolved in ethanol (100 ml), methanesulfonic acid 1.0 g) was added, ether was added to the cloud point and the solution was kept in the freezer to give 2.0 g of the pure compound, m.p. 210-212.
EXAMPLE 48 4-(6-lndazolamino)-6-methoxy-2-phenyl-7-trifluoromethylquinoline Methanesulfonate a. 4-Hydroxy-6-methoxy-7-trifluoromethyl-2- phenylquinoline (11.2 g) [prepared by the general procedure of 8.1. Bangdiwala, C.M. Desai, Jour. Indian Chem. Soc. 31, 43 (1954)] was dissolved in phosphorous oxychloride 100 ml) and refluxed for 40 minutes. it was then poured on ice and neutralized with strong ammonia. The precipitate (11.5 g) was filtered off and crystallized from ethanol (900 ml) to give 10.3 g of the pure product, m.p. 172.
b. -Aminoindazole (1.33 g; 10 mM) was dissolved in acetonitrile (50 ml) and concentrated hydrochloric acid (0.1 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (25 ml) to the mixture. 4-Chloro-6-methoxy-7- trifluoromethyl-Z-phenylquinoline (3.37 g; 10 mM) was added and the reaction mixture refluxed for 3 hr. and cooled to room temperature. The precipitated material (3.8 g) was suspended in hot ethanol (100 ml) and concentrated ammonium hydroxide (25 ml) was added to give a clear solution. The free base was precipitated by the addition of 800 ml water. 3.3 g of the free base were suspended in hot ethanol (100 ml), methanesulfonic acid (730 mg; 1 eq) was added to give 3.4 g of the methanesulfonate salt which on recrystallization from ethanol/water (2 times) gave 2.4 g of the pure product, m.p. 340342.
EXAMPLE 49 4-(6-lndazolamino)quinaldine Methanesulfonate 6-Aminoindazole (13.3 g; 0.1 M) was dissolved in acetonitrile (500 ml) and concentrated hydrochloric acid (1.0 ml) was added. The partially precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (250 ml) to the mixture. 4- Chloroquinaldine (17.7 g; 0.1 M) was added and the reaction mixture refluxed for 2% hours and cooled to room temperature. The precipitated material (28.5 g) was dissolved in a hot mixture of ethanol (500 ml) and water ml), concentrated ammonium hydroxide (60 ml) was added to the cooled solution and then diluted with water (2 liters). The precipitated free base (25.0 g) was dissolved in ethanol (650 ml) with wanning and methanesulfonic acid (8.75 g; 1 eq.) was added to yield 29.5 g of the methanesulfonate salt which on recrystallization (3 times) from ethanol gave 15.8 g of the product, m.p. 238,240.
EXAMPLE 50 4-(6-lndazolamino)-6-methoxyquinaldine Methanesulfonate 6-Aminoindazole (6.7 g) was dissolved in acetonitrile (400 ml) and concentrated hydrochloric acid (0.5 ml) was added. The precipitated hydrochloride salt was dissolved by the addition of dimethylformamide (200 ml) to the mixture. 4-Chloro-6-methoxyquinaldine 10.5 g) [Schock, J. Amer. Chem. Soc. 79, 1,672, 1,675 (1957)] was added and the reaction mixture refluxed for 4 hours. The precipitated material (16.5 g) was suspended in ethanol (150 ml), concentrated ammonium hydroxide (30 ml) was added and the free base was precipitated from the clear solution by the addition of water (800 ml). The base (14 g) was suspended in ethanol (150 ml) and methanesulfonic acid (7 g) was added. The precipitated methanesulfonate salt was recrystallized from ethanol (3 times) followed by crystallization from water to give 9 g of the product m.p. 202204. (The m.p. was 300 302 after recrystallization from ethanol).
EXAMPLE 51 2-Benzyl-4-(6-indazolamino)quinoline Methanesulfonate One-Third Hydrate G-Aminoindazole (320 mg) was dissolved in acetonitrile (12 ml) and concentrated hydrochloric acid (0.05 ml) was added. The precipitated hydrochloric salt was dissolved by the addition of dimethylformamide to the mixture. 2-Benzyl-4-chloroquinoline prepared by the method of A.K. Kiang, F.G. Mann, A.F. Prior, and A. Topham, J. Chem. Soc., 1,319 (1956)] (600 mg) was added and the solution was refluxed for 4 hours. The reaction mixture was cooled to room temperature and the product was filtered off and suspended in ethanol (25 m1). Aqueous ammonia was added to pH 9 followed by water (8 ml). The mixture was refrigerated and the free base filtered off. This material was vacuum dried (500 mg) and suspended in ethanol and methanesulfonic acid (137 mg; 1 equiv.) was added. The solution was evaporated to dryness and the residue recrystallized from ethanol to give 650 mg of the methanesulfonate, m.p. 253255 de'c.
EXAMPLE 52 4-(6-lndazolamino)-7-trifluoroquinaldine Methanesulfonate 7.5 g of 6-aminoindazole, 100 ml of acetonitrile, 0.7 m1 of concentrated hydrochloric acid, 50 ml of dimethylformamide and 13.8 g of 4-chloro-7-trifluoromethylquinaldine [prepared according to the procedure of G. Franchi, P. Vigne, Farmaco, Ed. Sci. 22 (11), 923-929 (1967)] were refluxed for 4 hours. The hydrochloride of the product formed a precipitate which was kept in the freezer overnight and the precipitate was filtered off. It was suspended in 200 ml hot ethanol; 35 ml of ammonium hydroxide was added. The free base dissolved to form a clear dark brown solution. 800 ml of water was added and the free base precipitated. The precipitate was taken up in acetone, evaporated and suspended in 100 ml of ethanol. 5.75 g of methanesulfonic acid was added to yield a clear solution which crystallized on cooling and was recrystallized from aqueous ethanol yielding 11.4 g, m.p. 305307.
EXAMPLE 53 4-(6-lndazolamino)-6,7-methylenedioxyquinaldine Methanesulfonate a. 33.5 g of 3,4-methylenedioxyaniline, 32 g of ethylacetoacetate, 100 ml of benzene and 4 drops of concentrated hydrochloric acid were refluxed for hours. 4.5 ml of water was separated and the benzene solution evaporated. A dark red oil, 62.3 g, was obtained which crystallized, m.p. 80-82.
b. 150 ml of diphenylether was refluxed. 63 g of the product (a) was dissolved in 60 ml diphenylether and added dropwise within 25 minutes. Precipitation took place during cyclization; heating was continued for 3% hours. The reaction mixture was kept at room temperature overnight. The precipitate was filtered off and washed with petroleum ether. 4-hydroxy-6,7- methylenedioxyquinaldine as a brown powder, 44 g, m.p. 347 dec. was obtained.
c. g of 6,7-Methylenedioxy-4-hydroxyquinaldine and 700 ml of phosphorus oxychloride were refluxed for hours. A clear brown solution formed. Excess phosphorus oxychloride was evaporated. The pH was adjusted to 7 with ammonium hydroxide. The precipitation was filtered off and washed with water. The product was recrystallized from a 200 ml methanol/70 ml water mixture. 8.2 g m.p. 13013l of the product was obtained.
d. 3.7 g of 6-Aminoindazole, 75 ml of acetonitrile, 0.33 ml of concentrated hydrochloric acid, 30 ml of dimethylformamide and 6.1 g of 4-chloro-6,7- methylenedioxy-2-methylquinoline were refluxed for 4% hours. The precipitate was kept overnight at room temperature and then filtered off, yielding 9.8 g, m.p. 365 dec. it was suspended in 150 ml of hot ethanol; 50 ml of ammonium hydroxide was added. The free base dissolved to fonn a clar solution. 800 ml of water was added and the free base precipitated after a few min utes, yielding 9.1 g, m.p. 256-258. It was suspended in 200 ml ethanol, heated, and 3.3 g of methanesulfonic acid was added to form a clear solution which precipitated after a few minutes. It was dissolved by adding 100 ml ethanol/50 ml water, yielding 7.6 g, m.p. 288-290.
EXAMPLE 54 7-Fluoro-4-( 6-indazolamino )quinaldine fonate Methanesul- 5 6-Aminoindazole 13.6 g (0.103 m) was dissolved in 500 ml acetonitrile, 1.0 ml concentrated hydrochloric acid was added, 250 ml dimethylformamide added to dissolve the hydrochloride salt, and 4-chloro-7- fluoroquinaldine [prepared by procedure of A.K. Sen,
10 U.P. Basu, J. Ind. Chem. Soc. 37, 836-838 (1957)] was 15 free base was filtered off. It was suspended in 500 ml of ethanol and 8.7 g of methanesulfonic acid was added. The solution was evaporated to dryness and the residue was recrystallized in ethanol/ether, m.p. 309-31l.
What is claimed is:
1. A compound of the formula l N E R5 t R3 l NIH:
wherein R is hydrogen or halogen;
R, is hydrogen, primary and secondary lower alkyl of one to six carbon atoms, benzyl, phenyl, pbromophenyl, p-chlorophenyl, or trifluoromethyl; each of R, and R is hydrogen, hydroxy, halogen, primary and secondary lower alkyl of one to six carbon atoms, lower alkoxy of one to four carbon atoms, or when R, is hydrogen, R is also trifluoromethyl; or R, and R, are methylenedioxy when combined and adjacent;
R is hydrogen or lower alkyl of one to six carbon atoms;
R, is hydrogen or primary and secondary lower alkyl of one to six carbon atoms, and wherein the amino bridge is attached to indazole at the 3-, 4-, 5-, 6- or 7- position; the pharmaceutically acceptable acid addition salts, or the N-oxides thereof, wherein the oxide is at the 1-position of the quinoline moiety.
2. A compound as defined in claim 1 which is 4-(5- indazolamino)-quinaldine.
3. A compound as defined in claim 1 which is 4-( 6- chloro-3-indazolamino)-quinaldine.
4. A compound as defined in claim 1 which is 4-(6- indazolamino)-quinaldine.
S. A compound as defined in claim 1 which is 4-(6- indazolamino)-2-trifluoromethylquinoline.
6. A compound as defined in claim 1 which is 2-(4- chlorophenyl)-4-(6-indazolamino)quinoline. I
7. A compound as defined in claim 1 which is 7.-
chloro-4-(6-indazolamino)quinaldine.
8. A compound as defined in claim 1 which is 4-(6- indazolamino)-6-methoxyquinoline.
28 indazolamino)-6-methoxyQ-phenylquinoline.
14. A compound as defined in claim 1 which is 4-(6- indazolamino)-6-hydroxy-2phenylquinoline.
15. A compound as defined in claim I which is 4-(6- indazolamino)-6-methoxy-2phenyl-7-trifluoromethylquinoline.
16. A compound as defined in claim 1 which is 4-(6- indazolamino )quinaldine.
Claims (15)
- 2. A compound as defined in claim 1 which is 4-(5-indazolamino)-quinaldine.
- 3. A compound as defined in claim 1 which is 4-(6-chloro-3-indazolamino)-quinaldine.
- 4. A compound as defined in claim 1 which is 4-(6-indazolamino)-quinaldine.
- 5. A compound as defined in claim 1 which is 4-(6-indazolamino)-2-TRIFLUOROMETHYLQUINOLINE.
- 6. A compound as defined in claim 1 which is 2-(4-chlorophenyl)-4-(6-indazolamino)quinoline.
- 7. A compound as defined in claim 1 which is 7-chloro-4-(6-indazolamino)quinaldine.
- 8. A compound as defined in claim 1 which is 4-(6-indazolamino)-6-methoxyquinoline.
- 9. A compound as defined in claim 1 which is 6-chloro-4-(6-indazolamino)-2-phenylquinoline.
- 10. A compound as defined in claim 1 which is 4-(6-indazolamino)quinoline.
- 11. A compound as defined in claim 1 which is 4(6-indazolamino)-2-phenylquinoline.
- 12. A compound as defined in claim 1 which is 4-(6-indazolamino)-7-methyl-2-phenylquinoline.
- 13. A compound as defined in claim 1 which is 4-(6-indazolamino)-6-methoxy-2-phenylquinoline.
- 14. A compound as defined in claim 1 which is 4-(6-indazolamino)-6-hydroxy-2-phenylquinoline.
- 15. A compound as defined in claim 1 which is 4-(6-indazolamino)-6-methoxy-2-phenyl-7-trifluoromethyl-quinoline.
- 16. A compound as defined in claim 1 which is 4-(6-indazolamino)quinaldine.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15906171A | 1971-07-01 | 1971-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3755332A true US3755332A (en) | 1973-08-28 |
Family
ID=22570921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US00159061A Expired - Lifetime US3755332A (en) | 1971-07-01 | 1971-07-01 | Substituted 4 indazolaminoquinolines |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3755332A (en) |
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919238A (en) * | 1973-06-06 | 1975-11-11 | Morton Norwich Products Inc | 9-(Substituted amino)imidazo(4,5-f) quinolines |
| US3992382A (en) * | 1973-06-15 | 1976-11-16 | The Upjohn Company | Quinolylaminobenzoylpiperazine-1-oxides |
| FR2509728A1 (en) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | NOVEL QUINOLINE DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME |
| EP0336544A1 (en) * | 1988-02-25 | 1989-10-11 | Smithkline Beecham Intercredit B.V. | Heteroaryl 4-amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion |
| US5304554A (en) * | 1990-04-27 | 1994-04-19 | Emory University | 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation |
| WO1998013350A1 (en) * | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| US5817520A (en) * | 1991-12-20 | 1998-10-06 | Oxis International S.A. | Spectrophotometric methods for assaying total mercaptans, reduced glutathione (GSH) and mercaptans other than GSH in an aqueous medium reagents and kits for implementing same |
| WO2000056738A1 (en) * | 1999-03-23 | 2000-09-28 | Astrazeneca Ab | Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| WO2001016139A1 (en) * | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| WO2002012226A1 (en) * | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| US6455520B1 (en) | 1998-09-25 | 2002-09-24 | Astra Zeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| WO2003028720A1 (en) * | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| US6579872B1 (en) | 1998-05-15 | 2003-06-17 | Astrazeneca Ab | Bezamide derivatives for the treatment of diseases mediated by cytokines |
| US6593333B1 (en) | 1998-10-01 | 2003-07-15 | Astrazeneca Ab | Substituted anilino-quinazoline (or quinoline) compounds and use thereof |
| US20040132781A1 (en) * | 2000-12-21 | 2004-07-08 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
| US20040147540A1 (en) * | 2001-06-26 | 2004-07-29 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
| US20050038081A1 (en) * | 1991-09-19 | 2005-02-17 | Astrazeneca | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| US20050137395A1 (en) * | 2003-12-23 | 2005-06-23 | Agouron Pharmaceuticals, Inc. | Novel quinoline derivatives |
| JP2005529954A (en) * | 2002-06-17 | 2005-10-06 | スミスクライン ビーチャム コーポレーション | Chemical process |
| US20050261339A1 (en) * | 2002-05-31 | 2005-11-24 | Norihito Ohi | Pyrazole compound and medicinal composition containing the same |
| US7008945B1 (en) | 1999-03-17 | 2006-03-07 | Astrazeneca Ab | Amide derivatives |
| JP2006519846A (en) * | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | Heterocyclic kinase inhibitors: methods of use and synthesis |
| US20060241115A1 (en) * | 2004-01-23 | 2006-10-26 | Michele Potashman | Compounds and methods of use |
| US20060252777A1 (en) * | 2004-11-30 | 2006-11-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| US20070123570A1 (en) * | 2002-07-19 | 2007-05-31 | Schumacher Richard A | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| US20080312232A1 (en) * | 2005-04-27 | 2008-12-18 | Amgen Inc. | Substituted amide derivatives and methods of use |
| US20090023795A1 (en) * | 2006-01-31 | 2009-01-22 | Robert Groneberg | Kinase Inhibitors And Methods Of Use Thereof |
| US20090143422A1 (en) * | 2003-03-03 | 2009-06-04 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| US20090149454A1 (en) * | 2007-10-29 | 2009-06-11 | Amgen Inc. | Benzomorpholine derivatives and methods of use |
| US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
| US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| US20100137324A1 (en) * | 2001-03-23 | 2010-06-03 | Dhanaphalan Nagarathnam | Rho-kinase inhibitors |
| US7750154B2 (en) | 2003-10-24 | 2010-07-06 | Astrazeneca Ab | Amide derivatives |
| JP2010536846A (en) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | Indole and indazole compounds as cell necrosis inhibitors |
| US20130296363A1 (en) * | 2010-09-01 | 2013-11-07 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
| WO2017091661A1 (en) * | 2015-11-25 | 2017-06-01 | Strovel Jeffrey William | Bicyclic bet bromodomain inhibitors and uses thereof |
| US10266536B2 (en) | 2013-03-14 | 2019-04-23 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
| CN110117278A (en) * | 2018-02-07 | 2019-08-13 | 复旦大学 | Benzo five-membered (hexa-atomic) heterocyclic amine compound of alkoxy and its medicinal usage |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3470186A (en) * | 1967-06-02 | 1969-09-30 | American Cyanamid Co | Substituted 4-anilino-3-quinolinecarboxylic acids and esters |
| US3524858A (en) * | 1967-05-18 | 1970-08-18 | Warner Lambert Pharmaceutical | 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid |
| US3637710A (en) * | 1969-05-26 | 1972-01-25 | Geigy Chem Corp | 4-(phenylimino)-1 4-dihydroquinoline derivatives |
| US3679687A (en) * | 1970-09-11 | 1972-07-25 | Ciba Geigy Corp | Derivatives of 4-{8 2-(carbocycloalkoxymethyl) phenylimino{9 -1,4-dihydroquinolines |
-
1971
- 1971-07-01 US US00159061A patent/US3755332A/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3524858A (en) * | 1967-05-18 | 1970-08-18 | Warner Lambert Pharmaceutical | 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid |
| US3470186A (en) * | 1967-06-02 | 1969-09-30 | American Cyanamid Co | Substituted 4-anilino-3-quinolinecarboxylic acids and esters |
| US3637710A (en) * | 1969-05-26 | 1972-01-25 | Geigy Chem Corp | 4-(phenylimino)-1 4-dihydroquinoline derivatives |
| US3679687A (en) * | 1970-09-11 | 1972-07-25 | Ciba Geigy Corp | Derivatives of 4-{8 2-(carbocycloalkoxymethyl) phenylimino{9 -1,4-dihydroquinolines |
Cited By (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919238A (en) * | 1973-06-06 | 1975-11-11 | Morton Norwich Products Inc | 9-(Substituted amino)imidazo(4,5-f) quinolines |
| US3992382A (en) * | 1973-06-15 | 1976-11-16 | The Upjohn Company | Quinolylaminobenzoylpiperazine-1-oxides |
| FR2509728A1 (en) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | NOVEL QUINOLINE DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME |
| EP0336544A1 (en) * | 1988-02-25 | 1989-10-11 | Smithkline Beecham Intercredit B.V. | Heteroaryl 4-amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion |
| US5006535A (en) * | 1988-02-25 | 1991-04-09 | Smith Kline & French Laboratories Ltd. | Substituted heterocylic 4-aminoquinoline derivatives as gastric acid secretion inhibitors |
| US5304554A (en) * | 1990-04-27 | 1994-04-19 | Emory University | 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation |
| US7772432B2 (en) | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| US20050038081A1 (en) * | 1991-09-19 | 2005-02-17 | Astrazeneca | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| US5817520A (en) * | 1991-12-20 | 1998-10-06 | Oxis International S.A. | Spectrophotometric methods for assaying total mercaptans, reduced glutathione (GSH) and mercaptans other than GSH in an aqueous medium reagents and kits for implementing same |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| US6809097B1 (en) * | 1996-09-25 | 2004-10-26 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
| WO1998013350A1 (en) * | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| US6579872B1 (en) | 1998-05-15 | 2003-06-17 | Astrazeneca Ab | Bezamide derivatives for the treatment of diseases mediated by cytokines |
| US6956037B2 (en) | 1998-05-15 | 2005-10-18 | Astrazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
| US6455520B1 (en) | 1998-09-25 | 2002-09-24 | Astra Zeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| US6593333B1 (en) | 1998-10-01 | 2003-07-15 | Astrazeneca Ab | Substituted anilino-quinazoline (or quinoline) compounds and use thereof |
| US6716847B2 (en) | 1998-10-01 | 2004-04-06 | Astrazeneca Ab | Substituted anilino-quinoline compounds and use thereof |
| US20060281734A1 (en) * | 1999-03-17 | 2006-12-14 | Brown Dearg S | Amide derivatives |
| US7008945B1 (en) | 1999-03-17 | 2006-03-07 | Astrazeneca Ab | Amide derivatives |
| US7332483B2 (en) | 1999-03-17 | 2008-02-19 | Astrazeneca Ab | Amide derivatives |
| US7442704B2 (en) | 1999-03-17 | 2008-10-28 | Astrazeneca Ab | Amide derivatives |
| WO2000056738A1 (en) * | 1999-03-23 | 2000-09-28 | Astrazeneca Ab | Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| US6784174B1 (en) | 1999-03-23 | 2004-08-31 | Astrazeneca Ab | Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| US20070167445A1 (en) * | 1999-08-27 | 2007-07-19 | Higuchi Robert I | Androgen receptor modulator compounds and methods |
| WO2001016139A1 (en) * | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| US6462038B1 (en) | 1999-08-27 | 2002-10-08 | Ligand Pharmaceuticals, Inc. | Androgen receptor modulator compounds and methods |
| JP2003508402A (en) * | 1999-08-27 | 2003-03-04 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Androgen receptor modulator compounds and methods |
| US20030199491A1 (en) * | 2000-08-09 | 2003-10-23 | Hennequin Laurent Francois Andre | Quinoline derivatives having vegf inhibiting activity |
| US7371765B2 (en) | 2000-08-09 | 2008-05-13 | Astrazeneca Ab | Quinoline derivatives having VEGF inhibiting activity |
| WO2002012226A1 (en) * | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| US20080312273A1 (en) * | 2000-08-09 | 2008-12-18 | Laurent Francois Andre Hennequin | Quinoline Derivatives Having Vegf Inhibiting Activity |
| CN1315822C (en) * | 2000-08-09 | 2007-05-16 | 阿斯特拉曾尼卡有限公司 | Quinoline derivatives having VEGF inhibiting activity |
| AU2001276536B9 (en) * | 2000-08-09 | 2002-02-18 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| AU2001276536B2 (en) * | 2000-08-09 | 2007-01-04 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| US7087603B2 (en) * | 2000-12-21 | 2006-08-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20040132781A1 (en) * | 2000-12-21 | 2004-07-08 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
| US20100137324A1 (en) * | 2001-03-23 | 2010-06-03 | Dhanaphalan Nagarathnam | Rho-kinase inhibitors |
| US7166612B2 (en) * | 2001-06-26 | 2007-01-23 | Beth Israel Deaconess Medical Center | Methods for reducing platelet activation platelet aggregaton or thrombosis |
| US20040147540A1 (en) * | 2001-06-26 | 2004-07-29 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
| US20070060605A1 (en) * | 2001-06-26 | 2007-03-15 | Flaumenhaft Robert C | Compositions and methods for inhibiting platelet activation and thrombosis |
| EA007430B1 (en) * | 2001-09-26 | 2006-10-27 | Фармация Италия С.П.А. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| US7511136B2 (en) | 2001-09-26 | 2009-03-31 | Pfizer Italia S.R.L. | Aminoindazole derivatives active as kinase inhibitors |
| WO2003028720A1 (en) * | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| EP1820503A3 (en) * | 2001-09-26 | 2008-05-21 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| JP2005512967A (en) * | 2001-09-26 | 2005-05-12 | フアルマシア・イタリア・エツセ・ピー・アー | Aminoindazole derivatives active as kinase inhibitors, processes for their preparation and pharmaceutical compositions containing them |
| US20040254177A1 (en) * | 2001-09-26 | 2004-12-16 | Raffaella Amici | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| US7429609B2 (en) * | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| US20050261339A1 (en) * | 2002-05-31 | 2005-11-24 | Norihito Ohi | Pyrazole compound and medicinal composition containing the same |
| US20060252943A1 (en) * | 2002-06-17 | 2006-11-09 | Amogh Boloor | Chemical process |
| AU2003276125B2 (en) * | 2002-06-17 | 2007-05-17 | Smithkline Beecham Corporation | Chemical process |
| EP1515955A4 (en) * | 2002-06-17 | 2006-05-03 | Smithkline Beecham Corp | Chemical process |
| JP2005529954A (en) * | 2002-06-17 | 2005-10-06 | スミスクライン ビーチャム コーポレーション | Chemical process |
| US20070123570A1 (en) * | 2002-07-19 | 2007-05-31 | Schumacher Richard A | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| US7655802B2 (en) * | 2002-07-19 | 2010-02-02 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| US20100093806A1 (en) * | 2002-07-19 | 2010-04-15 | Schumacher Richard A | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| US20090143422A1 (en) * | 2003-03-03 | 2009-06-04 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| US8017641B2 (en) | 2003-03-03 | 2011-09-13 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| US8518983B2 (en) * | 2003-03-03 | 2013-08-27 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| US20090149459A1 (en) * | 2003-03-03 | 2009-06-11 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| JP2006519846A (en) * | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | Heterocyclic kinase inhibitors: methods of use and synthesis |
| US7750154B2 (en) | 2003-10-24 | 2010-07-06 | Astrazeneca Ab | Amide derivatives |
| US20090069316A1 (en) * | 2003-12-23 | 2009-03-12 | Agouron Pharmaceuticals, Inc. | Novel quinoline derivatives |
| US20050137395A1 (en) * | 2003-12-23 | 2005-06-23 | Agouron Pharmaceuticals, Inc. | Novel quinoline derivatives |
| US7381824B2 (en) | 2003-12-23 | 2008-06-03 | Agouron Pharmaceuticals, Inc. | Quinoline derivatives |
| US7923457B2 (en) | 2003-12-23 | 2011-04-12 | Agouron Pharmaceuticals Inc. | Quinoline derivatives |
| US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
| US20060241115A1 (en) * | 2004-01-23 | 2006-10-26 | Michele Potashman | Compounds and methods of use |
| US20090176774A1 (en) * | 2004-01-23 | 2009-07-09 | Amgen Inc. | Compounds and methods of use |
| US8178557B2 (en) | 2004-01-23 | 2012-05-15 | Amgen Inc. | Compounds and methods of use |
| US7435823B2 (en) | 2004-01-23 | 2008-10-14 | Amgen Inc. | Compounds and methods of use |
| US20060252777A1 (en) * | 2004-11-30 | 2006-11-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
| US20110118252A1 (en) * | 2005-04-27 | 2011-05-19 | Amgen Inc. | Substituted amide derivatives and methods of use |
| US8685983B2 (en) | 2005-04-27 | 2014-04-01 | Amgen Inc. | Method of treating cancer with substituted amide derivatives |
| US7858623B2 (en) | 2005-04-27 | 2010-12-28 | Amgen Inc. | Substituted amide derivatives and methods of use |
| US20080312232A1 (en) * | 2005-04-27 | 2008-12-18 | Amgen Inc. | Substituted amide derivatives and methods of use |
| US8088794B2 (en) | 2005-04-27 | 2012-01-03 | Amgen Inc. | Substituted amide derivatives and methods of use |
| US20110124878A1 (en) * | 2006-01-31 | 2011-05-26 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
| US8039639B2 (en) | 2006-01-31 | 2011-10-18 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
| US8044083B2 (en) | 2006-01-31 | 2011-10-25 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
| US20090023795A1 (en) * | 2006-01-31 | 2009-01-22 | Robert Groneberg | Kinase Inhibitors And Methods Of Use Thereof |
| JP2010536846A (en) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | Indole and indazole compounds as cell necrosis inhibitors |
| EP2178870A4 (en) * | 2007-08-17 | 2012-04-11 | Lg Life Sciences Ltd | INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF CELL NECROSIS |
| US7795254B2 (en) | 2007-10-29 | 2010-09-14 | Amgen Inc. | Benzomorpholine derivatives and methods of use |
| US20090149454A1 (en) * | 2007-10-29 | 2009-06-11 | Amgen Inc. | Benzomorpholine derivatives and methods of use |
| US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| US20130296363A1 (en) * | 2010-09-01 | 2013-11-07 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
| US10266536B2 (en) | 2013-03-14 | 2019-04-23 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
| US10717739B2 (en) | 2013-03-14 | 2020-07-21 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
| WO2017091661A1 (en) * | 2015-11-25 | 2017-06-01 | Strovel Jeffrey William | Bicyclic bet bromodomain inhibitors and uses thereof |
| US10508106B2 (en) | 2015-11-25 | 2019-12-17 | Convergene Llc | Bicyclic BET bromodomain inhibitors and uses thereof |
| US11028079B2 (en) | 2015-11-25 | 2021-06-08 | Convergene, Llc | Small molecule BET bromodomain inhibitors and uses thereof |
| AU2016361441B2 (en) * | 2015-11-25 | 2021-08-12 | Convergene Llc | Bicyclic BET bromodomain inhibitors and uses thereof |
| EP4050005A1 (en) * | 2015-11-25 | 2022-08-31 | Convergene Llc | Bicyclic bet bromodomain inhibitors and uses thereof |
| CN110117278A (en) * | 2018-02-07 | 2019-08-13 | 复旦大学 | Benzo five-membered (hexa-atomic) heterocyclic amine compound of alkoxy and its medicinal usage |
| EP3750890A4 (en) * | 2018-02-07 | 2021-08-11 | Fudan University | ALCOXYBENZO FIVE-MEMBER (SIX-MEMBER) HETEROCYCLIC AMINE COMPOUND AND ITS PHARMACEUTICAL USES |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3755332A (en) | Substituted 4 indazolaminoquinolines | |
| US3594480A (en) | Nitrogen heterocycles for therapeutic administration | |
| US3753993A (en) | 1,4-dihydro-4-oxo-7-pyridyl-3-quinoline-carboxylic acid derivatives | |
| US4017622A (en) | Piperazine derivatives | |
| EP0553191B1 (en) | Pyridine and pyridine n-oxide derivatives of diarylmethyl- piperidines or piperazines, compositions and use thereof | |
| US4698348A (en) | 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents | |
| EP0140116B1 (en) | A 6-fluoro-1,4-dihydro-4-oxo-7-substituted piperazinyl-quinoline-3-carboxylic acid derivative and the method for preparing the same | |
| US3890319A (en) | (2-imidazolin-2-y(amino) substituted quinolines, -quinoxalines and -quinazolines as antihypertensive agents | |
| US4698346A (en) | Thiazolo[5,4-h]quinoline compounds useful as anti-allergy agents | |
| JPS63280078A (en) | Hetero bicyclic quinolone derivative | |
| CA2117224A1 (en) | Quinolonecarboxylic acid derivatives, their production and use | |
| US3993656A (en) | 1,8-Naphthyridine compounds | |
| US3563981A (en) | Alkylidene aromatic-aminomethylene-malonates and their preparation | |
| US5837705A (en) | Alpha-substituted pyridazino quinoline compounds | |
| NO129745B (en) | ||
| EP0172004B1 (en) | Quinolinones, process for their preparation and pharmaceutical compositions containing them | |
| JPH02282384A (en) | 5-substituted-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate antibacterial agent | |
| US3429887A (en) | 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation | |
| US3075981A (en) | 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation | |
| US3989709A (en) | Fused ring benzimidazole derivatives | |
| US3075984A (en) | 1-[(lower-aromatic)-(lower-alkyl)]-4-[(lower-aromatic)-(lower-alkyl) imino]-1, 4-dihydroquinolines and their preparation | |
| EP0178388A1 (en) | Quinolinecarboxylic acid derivatives | |
| US4442109A (en) | 3-Methylthiomethyl-and 3-methylsulfinylmethyl-4-quinolinones useful for treating hypertension | |
| US4044136A (en) | Aminoquinazoline therapeutic agents | |
| US4587341A (en) | 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials |